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Role in Colitis-Associated Colon Tumorigenesis 
 
Crystal Morales, Ph.D. 
University of Connecticut, 2013 
 Gp96, a mammalian endoplasmic reticulum resident chaperone, is required for the 
proper folding and expression of multiple Toll-Like Receptors (TLRs) and integrins. The 
expression of this heat shock protein (HSP) is elevated in cancer, and it is known to 
cross-present tumor antigens. A better understanding of gp96 biology will aid the design 
of cancer drugs, as gp96 is a target. To study this molecule, we investigated an 
orthologous system in Drosophila, a fruitful approach used in understanding HSP90 
biology. A BLAST search using the mammalian gp96 sequence identified Drosophila 
gp93, an uncharacterized molecule. With 74% amino acid homology and various 
conserved elements, we hypothesized that gp93 was a gp96 ortholog. This gene was 
therefore cloned and transduced into a murine pre-B cell line deficient for gp96. It was 
next tested whether or not gp93 could functionally compensate for gp96-loss by rescuing 
gp96 client expression. Despite the long evolutional gap, gp93 was indeed able to rescue 
gp96 client expression in mouse cells, albeit to a lower expression level than gp96. It was 
further demonstrated that CNPYb is a TLR-specific cochaperone of gp93, similar to the 
gp96 cochaperone CNPY3. Important residues in each molecule were then elucidated. 
Crystal Morales – University of Connecticut, 2013  
Therefore, we have not only identified gp93 as the Drosophila ortholog of gp96, but we 
have also established a simpler system by which to further study gp96 biochemistry.  
 Since gp96, TLRs, and macrophages have all been implicated in cancer, we 
decided to further explore their role in tumor initiation and progression. We utilized a 
macrophage-specific gp96 knockout (KO) mouse model to study the role of macrophage 
derived gp96 in tumorigenesis. Both wild type and KO mice were treated with either 
Dextran Sulfate Sodium (DSS) alone to induce colitis, or Azoxymethane plus DSS to 
induce inflammation-associated colonic tumors. KO mice are protected from colitis and 
colon tumorigenesis, suggesting that macrophage intrinsic gp96 plays a promoting role in 
both diseases. Mechanistically, gp96 induces IL-17, IL-23, TNFα, Wnt signaling, and β–
catenin mutations while reducing CD4+ IFNγ+ cells. Our data thus help to explain the 
manner in which gp96 promotes cancer, thus identifying possible targets for therapeutic 
development.  
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 This introduction will start with a focus on gp96 biology, detailing what is known 
about this molecule. We will then move on to discuss the two major client families of 
gp96: TLRs and integrins. Next, we will discuss the cochaperone CNPY3 and its family 
members. Since we elucidate the Drosophila ortholog of gp96, we will then examine the 
Drosophila Toll, integrin, and CNPY families. As our experiments analyze the role of 
macrophage-specific gp96 in colitis and colon cancer, we will next review macrophage 
biology, including differentiation and subtypes, and consider what is already known 
about the role of macrophages in cancer. Furthermore, since TLRs signal via NF-κB, we 
next discuss the NF-κB pathway, and the role of NF-κB and TLRs in both colitis and 
colon cancer. The following section will examine various molecules and pathways 
associated with both cancer and our mouse model. Finally, we will consider the clinical 
aspects of colitis and colon cancer, thereby highlighting the significance of our work. The 
introduction will then end with an outline of the thesis.  
 
I. gp96  
The mammalian heat shock protein (HSP) gp96 is located in the endoplasmic reticulum 
(ER) and is ubiquitously expressed. A member of the HSP90 family, it is also known as 
HSP90B1, grp94, endoplasmin, TRA1, CaBP4, ERp99, ECGP, and HSPC4 (1, 2). Gp96 
is a chaperone with two major client families: Toll-like receptors (TLRs) and integrins. It 
is required for the folding of TLR1, TLR2, TLR4, TLR5, TLR6, TLR7, TLR8, and 
TLR9, but not TLR3 (3-5). It is also required to fold the integrins α1, α2, α4, αD, αE, αL, 
αM, αV, αX, β2, β5, β6, β7, and β8 (3, 6). Additionally, gp96 is required for expression 
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of the platelet GPIb-IX-V complex via folding GPIX directly (7). Refer to Table I for a 
list of gp96 clients.  
Besides being a chaperone, gp96 also plays a role in the ER-associated 
degradation (ERAD) pathway, where it associates with OS-9 which binds ERAD 
substrates and brings them in proximity to the ubiquitin ligase Hrd1 (8). Gp96 is also 
postulated to play a role in the unfolded protein response (UPR), as its absence leads to 
decreased XBP-1 splicing yet increased compensatory expression of calreticulin, 
calnexin, and GRP78 (9). Furthermore, gp96 contains various low and high affinity 
calcium binding sites, and may thus play a role in calcium storage (2). Gp96 was also 
thought to act as a kinase and an aminopeptidase, but this was later proven to be the result 
of contaminating proteins in the purified fraction. However, gp96 itself can be 
phosphorylated (10-12).  
 The structure of gp96 was first solved in 2007 when Dollins et al crystalized the 
purified protein. Present as a homodimer, the structure reveals a twisted V conformation 
with dimerization at the C-terminus. The N-terminus remains open and the structure does 
not change between bound ADP or AMP-PNP (13). The gp96 structure was later 
analyzed by small angle X-ray scattering and electron microscopy, which further 
confirmed the V shape of the dimer. Highly homologous, the structure of gp96 mirrors 
that of cytosolic HSP90 (14).  
Various structural elements of gp96 are well documented. The molecule contains 
an N-terminal signal peptide (SP) for targeting to the ER, while a C-terminal KDEL ER-
retention sequence prevents it from continuing down the secretory pathway. Moreover,  
the N-terminus contains an ATP-binding pocket, followed by a highly charged middle 
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domain, and then the C-terminal dimerization domain (2). While the ATP and 
dimerization domains are important for function, the charged middle domain is not 
required (3). Although at a low rate, gp96 has proven ATPase properties, and this ability 
is required for function (3, 15-17).  
 The gp96 protein is 803 amino acids long and the importance of various amino 
acids has been elucidated. In 1996, a stretch of 44 amino acids in the C-terminus (676-
719 in canine gp96) was demonstrated to act as the dimerization domain (18). Gp96 has 
five potential N-linked glycosylation sites and it is phosphorylated on threonine and 
serine residues (2, 10). The amino acid D159, which binds ATP, is important for 
chaperone function. The amino acid E103, important for ATP hydrolysis, is required for 
folding of TLRs but not integrins (3). Importantly, a potential client-binding domain was 
postulated from the gp96 crystal, where a methionine pair surrounded by hydrophobic 
residues in alpha helix C2 protrude outward from the structure (13). This domain, 
residues 652-678, was later verified to indeed be the client-binding domain for both TLRs 
and integrins. Moreover, the methionine pair was further proven to be critical for 
integrins but not TLRs (19).  
 Gp96 is intimately linked to innate immunity via TLRs. As thus, its expression is 
important for the function of macrophages which express high levels of TLRs (4). Gp96 
is also important for proper tissue compartmentalization of B cells due to integrins, and 
for optimal antibody responses to TLR agonists (20). These studies were carried out with 
conditional knockout mice. However, using pan inducible knockout mice, gp96 was 
further shown to be important for the pro- to pre-B transition, where cells were blocked 
and prevented from differentiating. Similarly, thymocytes were stopped at the double 
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negative stage (CD4
-
 CD8
-
), and thus no mature T cells developed. In contrast, myeloid 
cell development was unimpaired in these mice (6).  
 Gp96 has various clinical implications. Its expression in macrophages promotes 
endotoxin shock, yet it is protective against Listeria infection (4). Gp96 is also important 
in vesicular stomatitis virus (VSV) infection, where its absence prevents the envelope 
glycoprotein VSV-G from binding the cell, and thus prevents cell entry (21). Although 
primarily located in the ER, gp96 has been found on the cell surface (22). Utilizing a 
transgenic mouse with enforced surface gp96 expression, it was found that such 
localization induced lupus like autoimmune disease. Specifically, surface gp96 induced 
IL-12 production by DCs in a MyD88 dependent manner (23, 24). TLR4 not only caused 
inflammation in this model, but also induced Treg suppressive function (25). 
Furthermore, gp96 has proven to be a therapeutic target for this disease, where a chemical 
gp96-inhibitor relieved lupus symptoms (26).  
 Although cell surface expression of gp96 causes autoimmunity, its expression in 
tumor cells promotes anti-tumor immunity via cross-presentation of cellular antigens and 
the induction of tumor-specific T cells (27, 28). Even without enforced cell surface gp96 
expression, gp96 purified from tumors is an effective immunization inducing specific 
anti-tumor immunity via macrophages and both CD4 and CD8 T cells (29). This tumor-
specific immunogenicity of gp96 derives from chaperoned antigenic peptides which are 
cross-presented via MHC I (30). Moreover, gp96 expression is induced in various 
cancers, both spontaneous and chemically induced, as well as tumor associated 
macrophages (31, 32). Clinically, gp96 is the target of various cancer trials. The vaccine 
Vitespen, for instance, is a HSP-peptide complex modeled off of gp96 (33).  
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TLRs 
TLRs are a family of pattern recognition receptors (PRRs) which recognize various 
pathogen-associated molecular patterns (PAMPs) from bacteria, viruses, fungi, and 
parasites. Additionally, a few endogenous ligands have also been found, termed danger-
associated molecular patterns (DAMPs), such as HMGB1, HSPs, and degradation 
products of the extracellular matrix. As an important component of innate immunity, 
TLRs are a first line of defense which signal immune cells and turn on adaptive 
immunity. These receptors can be broadly grouped by their location. The majority of 
TLRs are present on the cell surface: TLR1, TLR2, TLR4, TLR5, and TLR6. Another 
group of TLRs are located within endosomes: TLR3, TLR7, TLR8, and TLR9. The 
former group recognizes mainly microbial membrane components such as proteins, 
lipoproteins, and lipids. The latter group recognizes foreign nucleic acids. Mice express 
TLR1-13, but TLR10 is nonfunctional. Meanwhile, humans only express TLR1-10 (34).  
 The cytoplasmic tail of TLRs recruits TIR domain containing adaptor proteins. 
All TLRs recruit MyD88 except for TLR3, which recruits TRIF. TLR4 is the only 
member which recruits both MyD88 and TRIF. However, this receptor first interacts with 
TRAM before recruiting TRIF (34). As well, both TLR2 and TLR4 interact with TIRAP 
before MyD88 recruitment (34, 35). MyD88 then interacts with various IRAK family 
members, which in turn activate various TRAF members, which then activate both NF-
κB and MAPK pathways. The TRIF cascade induces TRADD, Pellino-1, RIP1, and then 
both NF-κB and MAPK pathways. The MyD88-dependent pathway primarily stimulates 
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inflammatory cytokine production, while the TRIF pathway primarily stimulates a type I 
interferon response (34).  
 TLR1 and TLR6 can form a heterodimer with TLR2. The TLR1/2 dimer 
recognizes triacylated lipopeptides from mycoplasma and gram-negative bacteria, while 
the TLR2/6 dimer recognizes diacylated lipopeptides from mycoplasma and gram-
positive bacteria. The specificity of these dimers derives from structural differences 
between TLR1 and TLR6; specifically, a hydrophobic channel in TLR1 is missing from 
TLR6 (34, 36). The triacylated lipopeptide Pam3CSK4, for instance, is recognized by the 
TLR1/2 dimer. TLR2 further functions with the help of coreceptors, such as dectin-1 and 
CD36, which aid in PAMP recognition (34).  
 TLR3 recognizes foreign dsRNA, mainly from viruses. A synthetic analog, poly 
(I:C), is commonly used during experimentation. Receptor ligation results in the 
production of both proinflammatory cytokines and type I interferon. Since the structure 
was crystalized, TLR3 was determined to homodimerize at the C-terminus. The 
horseshoe-like shape allows for ligand binding at both the N and C termini at the convex 
lateral side (34).  
 TLR4 recognizes lipopolysaccharide (LPS), a constituent of the gram-negative 
outer membrane. The soluble LPS-binding protein (LBP) binds LPS, which is then bound 
by the cell surface CD14, and is then transferred to TLR4 in complex with another 
molecule, MD2. Receptor ligation can then trigger proinflammatory cytokine and type I 
interferon production (34). In Alzheimer’s disease and atherosclerosis, TLR4 has been 
found to heterodimerize with TLR6. In this situation, amyloid-β and oxidized low-
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density lipoprotein act as the ligands and produce a sterile inflammation. Furthermore, 
the CD36 scavenger receptor was found to regulate this pathway (37).  
 TLR5 recognizes bacterial flagellin, a protein of flagella. In particular, small 
intestinal lamina propria DCs express high levels of TLR5. These DCs can promote Th1 
and Th17 differentiation, as well as B cell differentiation into IgA producing plasma 
cells. TLR11 is a relative of TLR5. Although less is known about this TLR, it appears to 
recognize a profilin-like molecule in Toxoplasma gondii, as well as uropathogenic 
bacterial constituents (34).  
 TLR7 recognizes ssRNA from viruses. It can also recognize some small 
interfering RNAs, synthetic poly (U) RNA, resiquimod (R-848), imiquimod, and guanine 
analogs like loxoribine. In particular, TLR7 is expressed highly on pDCs where it induces 
a strong type I interferon response as well as proinflammatory cytokines. Ligand 
recognition occurs within endolysosomes. TLR8 is most similar to TLR7. In humans, 
TLR8 recognizes viral ssRNA and R-848. In mice however, the ligand is unknown, as 
TLR8 KO mice respond normally to such agonists (34).  
 TLR9 recognizes unmethylated CpG DNA, common in viruses and bacteria, yet 
rare in mammals (34). Specifically, it was determined that the sugar backbone of DNA is 
important for recognition (38). TLR9 is also stimulated by the hemozoin crystal which is 
a byproduct produced by Plasmodium falciparum. Ligation of this receptor induces a 
strong Th1 response, and it is highly expressed on pDCs (34). More recently, TLR9 was 
found to be post-translationally cleaved, yielding a functionally mature receptor. This 
cleavage appears to be carried out by a member of the cathepsin protease family (34, 39, 
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40). Another level of TLR9 regulation is achieved through granulin, a soluble cofactor 
which potentiates CpG-TLR9 binding and signaling (41).  
 TLRs 10-13 have yet to be fully characterized. However, TLR13 is a murine TLR 
located within the endosomes. Recently, Oldenburg et al discovered that the ligand for 
TLR13 is a conserved 23S ribosomal RNA sequence (42). Shortly after, Hidmark and 
colleagues found that TLR13 recognizes whole gram-positive bacteria, and specifically 
bacterial RNA. TLR13 signaling seems to be MyD88 and UNC93B dependent, and can 
induce both inflammatory cytokines and type I interferon (43).  
 
Integrins  
Integrins are a family of cell surface molecules consisting of an alpha and beta subunit. 
Mammals have 18 different alpha integrins (α1, α2, αIIb, α3, α4, α5, α6, α7, α8, α9, α10, 
α11, αD, αE, αL, αM, αV, and αX) and 8 beta integrins (β1, β2, β3, β4, β5, β6, β7, and 
β8; Table I) which heterodimerize to form 24 distinct dimers. Some integrins are 
restricted to certain tissues or cell types, such as αIIbβ3 on platelets and β2 integrins on 
leukocytes. Various structural elements of integrins have been characterized, such as the I 
domain important for ligand binding, and integrins can be grouped according to their 
ligand specificities: collagen, laminin, RGD, and leukocyte (44).  
Integrins link the extracellular matrix and other cells outside to the cytoskeleton 
inside the cell. Integrins can modulate various cellular processes such as polarity, shape, 
motility, adhesion, apoptosis, survival, proliferation, differentiation, gene expression, and 
haptotaxis. Two types of signaling can occur, either inside-out or outside-in. With inside-
out signaling, G-protein-coupled receptors signal a conformational change in the integrin 
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allowing for higher affinity ligand binding. This occurs with leukocyte extravasation 
from the blood through the endothelial barrier, causing the cell to stop instead of roll. 
Ligand binding with outside-in signaling also induces a conformational change in the 
integrin. This leads to interaction of the cytoplasmic tail with various adaptor proteins 
and enzymes which assemble into adhesion structures. (44)  
Besides being involved in many cellular processes, integrins serve as receptors for 
various bacteria and viruses. Mutations in β2 can cause leukocyte adhesion deficiency 
(LAD) (45). As such, they have become potential therapeutic targets for various 
conditions. Anti-α4 antibodies have been used for Crohn’s disease and other 
inflammatory bowel diseases, as well as for multiple sclerosis. Anti-β3 antibodies have 
even been used for thrombosis. Various other integrin antagonists have been designed for 
clinical use as well, such as for β2 (44, 45).  
 
CNPYs 
Gp96 requires a co-chaperone for folding TLR9, called CNPY3 (5). The CNPY family is 
highly conserved across the animal kingdom with four mammalian members: CNPY1, 
CNPY2, CNPY3, and CNPY4 (Table I). This small family is divided into two subgroups, 
where the first two members have shorter C-terminal sequences than the last two 
members. The CNPY family is similar to the Saposin-like proteins, in that they contain a 
characteristic pattern of six cysteine residues. All members have a signal peptide and ER 
retention signal. However, CNPY3 also contains a C-terminal basic region high in lysine 
residues. CNPY1 displays self-binding properties, and it is thus postulated that CNPYs 
form a Saposin-like dimeric structure (46).  
 11 
 
 CNPY3 is also known as PRAT4A (protein associated with TLR4 A) for its 
ability to regulate TLR4 cell surface expression and signaling (47). CNPY3 was later 
found to also play a role in regulating TLR1, TLR2, TLR7 and TLR9. Moreover, similar 
to gp96, CNPY3 does not regulate TLR3 (48). Three single-nucleotide polymorphisms 
(R95L, S231I, and M145K) were characterized in CNPY3, yet only M145K was found to 
alter function (49). As a cochaperone of gp96, the two molecules are found to physically 
interact, yet ATP causes complex dissociation. Since CNPY3 seems to bind the ATP-
sensitive form of gp96, it is postulated to promote client loading (5).  
 Other CNPY family members are not as well studied as CNPY3. CNPY4 for 
instance, also called PRAT4B (protein associated with TLR4 B), appears to regulate 
TLR4 cell surface expression similar to CNPY3. It is also conserved among various 
vertebrate species, and it is ubiquitously expressed in different tissues and leukocyte 
subsets (50). The most dissimilar family member, however, appears to be CNPY1. As 
opposed to the ubiquitous nature of CNPY3 and CNPY4, CNPY1 is restricted to neural 
tissues. In zebrafish, CNPY1 regulates FGF signaling along the midbrain-hindbrain 
boundary via its interaction with FGFR1 (46).  
 
II. Drosophila homologues    
Mammalian gp96 chaperones TLRs with the help of its cochaperone CNPY3, and it also 
chaperones integrins (3-6). An orthologous system would therefore not only contain a 
paralogue of gp96, but also similar client and cochaperone molecules. Next, we therefore 
explore these homologous genes in Drosophila, where Toll, integrin, and CNPY families 
also exist.  
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Toll  
Although mammalian TLRs are highly characterized, the original Drosophila Toll (Toll-
1) was discovered first. The first mammalian TLR was not discovered until 1997, which 
was TLR4 (51). Drosophila Toll, however, is not only important for innate immunity, but 
also for dorsal-ventral patterning of the embryo (52, 53). Drosophila contains nine Toll 
family members, Toll-1 to Toll-9 (Table I). They all consist of an ectodomain comprised 
of leucine rich repeats flanked by cysteine-rich domains. They also contain a 
transmembrane domain and cytosolic tails. Toll-5 is most similar to Toll-1 while Toll-9 is 
different from the other Tolls, containing only one cysteine-rich domain more 
characteristic of mammalian TLRs. Only Toll-1, however, has been definitively proven to 
be involved in innate immunity. Although some evidence exists for a role of Toll-5 and 
Toll-9 in immunity, this relationship has not been fully characterized (54).  
 Toll-1, similar to mammalian TLR4, requires accessory proteins in order to be 
activated. Fungal and yeast derived β-glucan is first recognized by GNBP3, while 
bacterial peptidoglycan is recognized by either PGRP-SD or PGRP-SA/GNBP1. These 
complexes then activate a protease cascade, starting with ModSP. This molecule in turn 
activates Grass, which then activates Spirit, Spheroide, or Sphinx1/2. These proteases 
then activate SPE, which cleaves Spatzle (Spz). Spz is released as an inactive protein, and 
when cleaved into the C-terminal 106 amino acids (C-106), serves as the direct ligand of 
Toll-1. Cell surface dimeric Toll-1 binds two C-106 dimers, initiating the downstream 
signaling cascade (54).  
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 Comparable to mammalian TLRs, the cytosolic tail of Toll-1 also contains a TIR 
domain which recruits adaptor molecules. The first adaptor recruited is the Drosophila 
MyD88 homolog, which then binds Tube and then Pelle. Then either Pelle directly 
phosphorylates Cactus, or it first recruits Cactus Kinase. Once phosphorylated, the 
inhibitory Cactus is degraded, thus releasing the Dif/Dorsal transcription factor to 
translocate to the nucleus. Various antimicrobial peptide genes are then transcribed, such 
as Drosomycin and Defensin, which stimulate an immune response for microbial 
clearance (54, 55).  
 
Integrins  
Drosophila integrins consists of both alpha and beta subunits which heterodimerize 
similar to the mammalian integrin family. Drosophila has five alpha integrins (αps1, αps2, 
αps3, αps4, and αps5), and only two beta integrins (βps and βν; Table I). βps (myospheroid) is 
widely expressed and can heterodimerize with each alpha subunit (44). βν expression is 
very restricted, only being expressed at 12-15 hours of embryogenesis, and selectively in 
the midgut endoderm (56). It is not essential for viability or fertility, and it can partially 
rescue loss of βps (57).  
 βps and αps1 dimerize to form the PS1 (position specific) integrin; βps and αps2 form 
PS2; βps and αps3 form PS3; and so on. The ligands for these integrins appear to be 
components of the extracellular matrix, such as collagen IV, tiggrin, laminins, and 
tenascin-m. Specifically, PS1 and PS2 are known to bind laminins, and PS2 can further 
bind tiggrin. PS3 is also thought to bind laminins. Other specific ligands are unknown. 
However, data suggests that there are multiple ligands for each integrin (58, 59).  
 14 
 
 Integrins αps1 (multiple edematous wings) and αps2 (inflated) are both expressed in 
the embryo, larva, and adults. Their expression patterns seem to be complimentary, with 
αps1 expressed in the ectoderm and αps2 in the mesoderm. Specifically, αps1 is highly 
expressed in the midgut primordia while αps2 appears to concentrate at muscle attachment 
sites, and both are expressed in the wing imaginal disc (60, 61). αps3 (scab, volado) is also 
expressed in all developmental stages: embryo, larva, and adult. It is expressed in the 
amnioproctodeal invagination, amnioserosa, midline of the ventral nerve cord, dorsal 
vessel, midgut, trachea, and salivary gland (62). Furthermore, PS1 and PS2 are expressed 
during early and mid-oogenesis, while PS3, PS4, and PS5 are expressed in late-oogenesis 
(59).  
 
CNPYs 
The CNPY family is highly conserved. In Drosophila, there are two family members: 
CNPYa and CNPYb (Table I). These CNPYs appear to also contain a signal peptide and 
ER retention sequence. The six saposin-like cysteine residues are also conserved in both 
Drosophila CNPYs. Furthermore, CNPYb has a highly basic region similar to CNPY3, 
although smaller in size. Meanwhile, CNPYa appears to be more similar to CNPY1 and 
CNPY2 (46). However, the function of the Drosophila CNPYs is unknown.  
 
III. Macrophages in cancer 
Macrophages have been implicated in promoting both colitis and cancer (63-66). 
However, which molecules and pathways are involved in this process is not completely 
understood. We believe that macrophage intrinsic gp96, in part via chaperoning TLRs, 
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promotes colitis and cancer. Therefore, we will next describe macrophages in general, 
and what is known in the literature about their role in colitis and cancer progression.  
 
Macrophages 
Macrophages are hematopoietic derived immune cells. Hematopoietic stem cells in the 
bone marrow give rise to myeloid progenitors which differentiate into monoblasts, pro-
monocytes, and then into monocytes. Monocytes leave the bone marrow to circulate in 
the blood and migrate to various tissues throughout the body. In the presence of CSF-1, 
these monocytes differentiate into macrophages. However, they can also give rise to 
osteoclasts in the presence of RANKL, or to myeloid DCs (67, 68). Multiple macrophage 
subsets exist in different tissues which differ in various ways: microglia in the brain, 
alveolar macrophages in the lung, Kupffer cells in the liver, and Langerhans cells in the 
skin, among others (69, 70).  
 Although macrophages are thought of as immune cells, they also play trophic 
roles in development. Macrophages are required for proper ductal branching, such as in 
the mammary gland and pancreatic islets. Microglia are important for neural networking, 
specifically within the hypothalamic-pituitary-gonadal axis and both excitatory and 
inhibitory signals in auditory and visual evoked potentials. Macrophages are also 
important for angiogenesis after wound healing, and in the eye, heart, and lungs. 
Macrophages even play roles in adipogenesis, myocyte development and growth, and 
erythrogenesis (68).  
 The immune functions of macrophages include phagocytosis/endocytosis and 
antigen presentation. Macrophages, present in high numbers, are the first line of defense 
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against an invading pathogen. They are able to phagocytize pathogens either directly or 
indirectly via PRRs. The phagocytized material is processed and then presented for 
activation of adaptive immunity via MHC I and II. The engagement of various PRRs 
results in the production of cytokines and chemokines. Macrophages also have 
microbicidal properties, and can fuse into giant cells (71).  
 In order to have diverse functions, macrophages must harbor different receptors 
and other molecules. For instance, macrophages express various PRRs, such as TLRs, 
NLRs, and C-type lectin receptors. They also express complement molecules, scavenger 
receptors, MHCI and II, costimulatory molecules, and integrins. Some common 
macrophage markers include CD11b, F4/80, CD68, CSF-1R, MAC2, CD163, and Marco 
(69-71).  
Macrophages can further be divided into classically- or alternatively-activated 
macrophages (M1 versus M2). While M1 cells are typically stimulated with IFNγ, M2 
cells are stimulated by IL-4 and IL-13, therefore being associated with either a Th1 or 
Th2 response, respectively. M1 cells are predominantly inflammatory, expressing IL-1, 
IL-6, IL-12, IL-23, TNFα, MHCII, CD86, Nos2, SOCS3, pSTAT1 and/or pSTAT3. M2 
cells are more suppressive, expressing IL-10, Dectin-1, Arg1, CCL12, CCL24, CXCL13, 
SOCS2, and pSTAT6. M2 macrophages are more similar to trophic macrophages (69-
71).  
 Macrophages within the small and large intestines are primarily located within the 
subepithelial lamina propria (72). These macrophages are unique, being highly 
phagocytic and bacterialcidal due to the constant presence of commensal bacteria within 
the gut. However, they weakly produce proinflammatory cytokines, and this phenotype is 
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induced by the intestinal stromal cells (67). Besides tolerance to commensals, intestinal 
macrophages must also be nonresponsive to food antigens (70). While they express 
various TLRs, they do not express CD14 or various Ig receptors. When stimulated by 
TLR ligands, however, these macrophages do not produce inflammatory cytokines. 
Instead, they act to maintain homeostasis in an environment with constant foreign stimuli. 
When pathogenic organisms invade into the lamina propria, however, blood monocytes 
are recruited which can induce a needed inflammatory response (72).  
Macrophages have been implicated in various diseases: cancer, rheumatoid 
arthritis, atherosclerosis, multiple sclerosis, Crohn’s disease, autoimmune hepatitis, diet-
induced obesity, type II diabetes, allergy, asthma, infection, and fibrosis (68, 70). In 
cancer, macrophages constitute a large percentage of cells within the tumor 
microenvironment and have thus been called Tumor Associated Macrophages (TAMs) 
(73). TAMs are more similar to alternatively activated macrophages (M2), and differ 
from classically activated macrophages (M1) in terms of secreted molecules, among other 
factors (74).  
 
Roles in colitis and cancer 
Macrophages harbor a promoting role in colitis. Patients with ulcerative colitis have 
increased numbers of CD14
+
 macrophages within the intestinal mucosa. These cells are 
activated by IgG
+
 plasma cells to produce inflammatory cytokines such as TNFα and IL-
1β. These macrophages are also stimulated by commensal bacteria to produce TNF and 
IL-23, and thus promote colitis progression (64). CD14
+
 macrophages are also increased 
in Crohn’s disease patients, and they produce more IL-6, IL-23, and TNFα than 
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macrophages in either normal controls or ulcerative colitis patients. In Crohn’s disease, 
these macrophages contribute to IFNγ production by lamina propria mononuclear cells 
(65). Therefore, macrophages promote both ulcerative colitis and Crohn’s disease.  
Jeffrey Pollard and colleagues have performed tremendous work on the tumor-
promoting roles of macrophages in vivo, primarily in the context of mammary cancers. 
Pollard first became interested in macrophage colony-stimulating factor (CSF-1, M-CSF) 
and its receptor CSF-1R due to the fact that the expression of both of these molecules is 
increased in breast, uterine, and ovarian cancers and that they correlate with poor 
prognosis and high grade (66). CSF-1 regulates differentiation, proliferation, and survival 
of monocytes (macrophages, microglia, and osteoclasts) (66, 75). However, both CSF-1 
and CSF-1R expression have been found in tumor cells, suggesting a direct role in tumor 
promotion (66).  
Mice with a recessive null mutation of CSF-1 (Csf1
op
), which have an almost 
complete absence of mature tissue macrophages, were crossed to transgenic mice that are 
susceptible to breast cancer (Polyoma Middle T oncoprotein, PyMT). Although primary 
tumor incidence and growth were not affected in these mice, the progression to invasive 
carcinoma and metastasis were delayed. As well, the recruitment of macrophages to the 
tumor microenvironment was also reduced. Furthermore, overexpression of CSF-1 
accelerated tumor progression and metastasis (66). Macrophages thus harbor tumor 
promoting capabilities.  
Within the Csf1
op
 PyMT mouse model, tumor cells only express EGFR while 
macrophages only express CSF-1R. The two cell types interact in a paracrine manner and 
migrate via EGF and CSF-1 gradients into microneedles. In this manner, macrophages 
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promote the migration of carcinoma cells away from the primary tumor, and thus 
promotes metastasis  (76). DeNardo and colleagues expanded upon this notion, 
discovering that CD4
+
 IL-4
+
 T cells directly promote macrophage secretion of EGF, 
which then signals tumor cells via EGFR (77). Furthermore, multiphoton microscopy 
demonstrated that tumor cells must associate with perivascular macrophages within the 
mammary tumor in order to intravasate when local angiogenesis is absent (78).  
Using Csf1
op
 PyMT mice, CD11b-DTR mice, and L-clodronate to deplete 
macrophages from mammary tumors by both genetic and chemical means, Pollard 
demonstrated that macrophages are important for cancer cell extravasation, metastatic 
seeding and subsequent growth, obtaining similar data from each model. For instance, 
when tumor cells are injected iv, they accumulate in the lung. However, the number of 
tumor cells drastically drop by 36 hours. The cells remaining have successfully seeded 
the lung, and then start to proliferate. L-clodronate treatment significantly decreased the 
number of seeded tumor cells. Not only do less metastatic nodules form, but the ones 
which grow are smaller in size. Furthermore, the phenotype of macrophages recruited 
into the metastatic site differs from resident macrophages. Recruited macrophages have 
similar F4/80 expression, but increased CD11b, CCR2, CX3CR1, and VEGFR1, yet 
decreased CD11c (63). Therefore, a distinct macrophage population is recruited which 
promotes tumor cell metastasis.  
Tumors must be in proximity to blood vessels in order to survive, grow, and 
metastasize. Not only can tumors utilize the host vasculature, but they can also promote 
angiogenesis within the tumor microenvironment. Moreover, the occurrence of tumor 
angiogenesis is associated with progression to malignancy. Again using the Csf1
op
 PyMT 
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model, Pollard’s group found that macrophages promote tumor angiogenesis. While 
Csf1
op
 PyMT mice had delayed angiogenesis, premature macrophage infiltration into 
premalignant tumors promoted early vasculature formation (79). In addition, these 
macrophages were newly recruited right before malignant progression, and were essential 
for angiogenesis (80).  
In order to uncover the role of vascular endothelial growth factor (VEGF-A) 
produced by TAMs in tumorigenesis, Pollard’s group genetically restored VEGF-A 
expression in mammary epithelial of PyMT mice, and hence in tumors. Compared to 
control mice, angiogenesis and tumor progression were restored with VEGF-A. 
Leukocyte infiltration was also induced, consisting predominantly of macrophages (81). 
Therefore, TAMs promote tumor angiogenesis via production of VEGF-A.  
Similar to Pollard’s data, Kubota used a CSF-1R inhibitor and blocking antibody 
in a mouse model of osteosarcoma. AX osteosarcoma cells were injected s.c. in the back, 
followed by daily s.c. injections of either the inhibitor or blocking antibody, creating a 
local decrease in monocyte differentiation. In this model, CSF1/CSF-1R inhibition 
resulted in decreased tumor growth, angiogenesis, lymphangiogenesis, metastasis, 
mortality, and macrophage infiltration into the tumor. Importantly, healthy angiogenesis 
and lymphangiogenesis were not affected, contrary to that seen with VEGF inhibition. 
Moreover, in vitro studies proved that the inhibitor only affects macrophages, and not AX 
cells (75).  
The use of clodronate encapsulated in liposomes has proven an effective chemical 
method for depleting macrophages. Although touched upon above in Pollard’s work, 
many other investigators have taken advantage of this reagent. Zeisberger and colleagues 
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used clodronate with human A673 rhabdomyosarcoma and murine F9 teratocarcinoma in 
mouse tumor models. Efficient depletion of TAMs resulted in decreased tumor growth 
and angiogenesis (82).  
From a clinical standpoint, the adverse role of macrophages in cancer can also be 
seen. For example, patients with classic Hodgkin’s lymphoma have large numbers of 
macrophages. Higher numbers of macrophages in these patients correlated with shorter 
progression-free survival, shorter disease-specific survival, and increased likelihood of 
relapse. Thus, macrophages can be used as a biomarker for risk stratification in 
Hodgkin’s lymphoma (83).  
Although the above mentioned literature defines a tumor promoting role of 
macrophages, various macrophage mediators have also been demonstrated. Coculture 
experiments of macrophages with breast cancer cell lines increased tumor cell 
invasiveness. Macrophages upregulated TNFα, which lead to increased secretion of 
matrix metalloproteases (MMPs). Inhibition of either TNFα or MMPs reduced 
invasiveness. Neither invasiveness nor induction of TNFα or MMPs was seen in 
cocultures of macrophages with a benign mammary epithelial cell line (84). Matsumoto 
demonstrated another macrophage mediator in colitis-associated premalignant cancer. 
Macrophages from treated mice were found to produce increased IL-6 and soluble IL6Ra, 
which signaled on gut epithelial cells inducing pSTAT3. Antagonizing the IL-6 
coreceptor (gp130) on epithelial cells significantly reduced disease (85).  
Another mediator of macrophage function is nitric oxide (NO), considered to be a 
M1 marker. In a model of skin cancer, transfer of CD8
+
 T cells lead to tumor cell killing. 
These T cells produced IFNγ, which activated macrophages to produce NO. Surprisingly, 
 22 
 
NO played a dual role, being required for tumor regression, yet suppressing CD8
+
 T cell 
activity (86). In another study, combined IL-1/anti-CD40 immunotherapy had anti-tumor 
effects in a renal cell carcinoma model. This treatment induced high NOS2/iNOS 
expression in macrophages. Both macrophage depletion and iNOS inhibition reduced the 
ability of the immunotherapy treatment to reduce lung metastases. However, NO did not 
play a role in primary tumor reduction (87). Additionally, higher levels of iNOS are seen 
in TAMs after irradiation therapy, as well as Arg1 and Cox2. Irradiated prostate cancer 
cells had quicker growth kinetics than unirradiated tumor cells, suggesting a tumor-
promoting role for iNOS, Arg1, and Cox2 in macrophages (88).   
Many tumor cells have an ER stress response which actually promotes tumor 
growth and progression. Curiously, secreted factors from such stressed tumor cells can 
activate ER stress within macrophages as well. These stressed macrophages then amplify 
an inflammatory response beneficial for tumor cells. Macrophage-specific TLR4 was 
identified to play a role in this transmission of ER stress to the macrophages, although 
TLR2 had no effect (89). Therefore, TLR4 plays a tumor promoting role in macrophages.  
 
IV. NF-κB in colitis and cancer  
The NF-B signaling pathway is the main pathway downstream of TLRs, and it has been 
implicated in both colitis and cancer (90-97). Since gp96 chaperones TLRs, we next 
describe the NF-B signaling pathway in general, and then explore what is known about 
its role in these two diseases.  
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NF-κB pathway  
NF-κB is a family of five similar transcription factors: RelA (p65), RelB, c-Rel, NF-κB1 
(p105/p50), and NF-κB2 (p100/p52). They combine as homo and heterodimers, and are 
inhibited by the binding of IκB in the cytosol. The IκB family consists of five members: 
IκBα, IκBβ, IκBγ, IκBε, and BCL3. Upon activation of various pathways, these inhibitors 
are phosphorylated by IKK kinase and degraded by the proteasome. The IKK family has 
three family members, IKKα, IKKβ, and IKKγ (NEMO). IKK itself is activated by NIK 
kinase. Once the IκB inhibitor is degraded, liberated NF-κB translocates to the nucleus 
where it acts as a transcription factor. Multiple pathways activate NF-κB, such as TLRs, 
TNFα, IL-1, IL-18, T cell receptor, B cell receptor, BAFF, CD40L, and lymphotoxin β. 
The NF-κB pathways can also regulate multiple events, such as proliferation, apoptosis, 
differentiation, inflammation, immune response, and even tumorigenesis (90, 91).  
 
NF-κB in colitis  
Myeloid differentiation factor 88 (MyD88) is an important adaptor molecule necessary 
for TLR, IL1R, and IL18R activation of NF-κB. MyD88 also engages IFNGR1, where it 
activates the p38 MAPK pathway (98). Three groups demonstrated the importance of 
MyD88 in intestinal homeostasis and protection from colitis utilizing the DSS model (92-
94). Rakoff-Nahoum showed that MyD88 KO mice dramatically lost weight and died 
after acute DSS treatment. Compared to WT mice, these KO mice had increased rectal 
bleeding, ulceration, erosion, and epithelial injury, while red blood cell concentration, 
hematocrit, and levels of IL-6 and CXCL1 were decreased. Using antibiotic treatments, 
TLRs were implicated as the potential upstream receptors involved. While WT mice had 
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100% survival rates for DSS-colitis, antibiotic treatment decreased survival to ~10%, 
similar to MyD88 KO mice treated with DSS. Furthermore, the addition of LPS or LTA 
ameliorated survival rates (92). However, this report does not investigate the potential 
roles of IL1R, IL18R, or IFNGR1.  
 Araki et al confirmed the protective role of MyD88 in acute DSS-colitis, where 
MyD88 KO mice  exhibited increased weight loss, bleeding, clinical and histological 
scores, and colonic shortening (93). Kirkland also demonstrated the increased mortality 
of MyD88 KO mice treated with DSS, but used a chronic model as opposed to an acute 
model. Contrary to Rakoff-Nahoum, antibiotic treatment ameliorated survival of both 
WT and MyD88 KO mice (94). DSS directly attacks epithelial barrier integrity, allowing 
exposure of the underlying lamina propria cells to gut commensal bacteria. It appears that 
direct sensing of commensals and the ensuing inflammation is protective during acute 
colitis, presumably promoting wound repair. During chronic colitis however, 
uncontrolled commensals proliferate and become systemic, where they can be found in 
the liver and lung, and lead to mortality (94). 
 The importance of Kirkland’s work is in the investigation of cell specific roles of 
MyD88 in colitis. Although epithelial cell specific MyD88 KO mice had no phenotype 
compared to WT mice treated with DSS, all other cell specific KO mice had decreased 
survival: B cells, T cells, DCs, and macrophages. While the later three cell specific mice 
had roughly 40-50% survival, only B cell specific MyD88 KO mice had 0% survival, 
similar to total MyD88 KO mice. It appeared that B cell specific MyD88 controlled lethal 
dissemination of commensals, where B cell activation of complement played a key role 
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(94). However, since TLRs are more prevalent in DCs and macrophages, it’s curious to 
know whether IL1R, IL18R, or IFNGR1 may also play protective roles in B cells.  
 Besides MyD88, other NF-κB pathway members also play roles in colitis. Nenci 
demonstrated that intestinal epithelial cell specific IKKγ (NEMO) KO mice developed 
spontaneous intestinal inflammation. These mice exhibited pathology characteristic of 
colitis, with shortened colons, bacterial translocation, and immune cell infiltration (CD4
+
 
T cells, DCs and granulocytes). These mice also had increased levels of cytokines and 
chemokines as early as two weeks of age, which became more pronounced over time. 
Furthermore, MyD88 and TNFR1 upstream of IKK were crucial for pathogenesis, as 
disease was ameliorated in KO mice crossed to either MyD88 or TNFR1 KO mice. The 
phenotype of spontaneous colitis was also recapitulated in IKKα/β double KO mice, but 
not in single KO mice, presumably due to compensation by the other (99). Although 
intestinal epithelial cell specific IKKβ KO does not lead to spontaneous colitis, Greten et 
al demonstrated that these mice are more susceptible to DSS-colitis. KO mice lost more 
weight, and had increased histological damage, ulceration, and expression of 
inflammatory cytokines than WT mice (100). Therefore, epithelial specific IKK is 
important for intestinal homeostasis, as well as amelioration of colitis.  
 Single immunoglobulin IL-1 receptor related molecule (SIGIRR/TIR8) is a 
negative regulator of TIR signaling, such as with IL1R and TLR. SIGIRR KO mice 
therefore have uninhibited signaling through these receptors. Under the DSS regimen 
these mice are highly susceptible, with 100% mortality by 13 weeks and high induction 
of inflammatory molecules. SIGIRR KO mice were then crossed to gut epithelial specific 
SIGIRR transgenic mice and then subjected to DSS-colitis. These mice had an 
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intermediate phenotype compared to WT or SIGIRR KO mice (101). Therefore, NF-κB 
induction plays a colitis promoting role in epithelial cells, as well as another cell type(s) 
not examined in this model. Collectively, these data demonstrate that NF-κB plays a 
promoting role in colitis (Table II).  
 
NF-κB in cancer  
As discussed in more detail below, mice with an autosomal dominant mutation within the 
adenomatous polyposis coli (APC) gene develop spontaneous multiple intestinal 
neoplasia (Min). These APC
Min
 mice develop numerous tumors in both the small and 
large intestines (102). Later, this phenotype was found to be mediated via MyD88. 
Rakoff-Nahoum et al demonstrated that compared to APC
Min/+ 
mice,  APC
Min/+
 MyD88 
KO mice had increased survival, hematocrit, and apoptotic tumor cells, while polyp 
number and size were decreased (95). Another group further demonstrated that the 
APC
Min
 phenotype was driven by TLR and EGF activation of ERK and subsequent 
increase in cMyc, leading to increased proliferation and reduced apoptosis in enterocytes, 
thereby promoting tumorigenesis (103).  
  A study by Hagemann and colleagues demonstrated that IKKβ polarized TAMs 
towards an alternatively activated phenotype with increased IL-10 and ARG1, yet 
decreased IL-12. When IKKβ was inhibited, macrophages reverted to a classical 
phenotype with increased iNos, IL-12, and tumoricidal activity, while IL-12 recruited NK 
cells (104). Although IKK seemed to protect against colitis as previously mentioned, here 
it promoted cancer.  
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 Swann et al showed the tumor promoting effects of MyD88 in two separate 
mouse models: DMBA+TPA induced skin papilloma, and MCA induced fibrosarcoma. 
Tumor incidence was significantly decreased in MyD88 KO mice under both models. 
The number of lesions was also decreased in the DMBA+TPA model. However, MyD88 
was not required for transplanted tumor rejection (96). Therefore, MyD88 appears to be 
more important for tumor initiation than for tumor progression.  
 Schiechl and colleagues discovered a colitis promoting role of MyD88 in 
oxazolone (Oxa)-induced colitis, as well as tumor promoting effects in an inflammation-
induced colon cancer model utilizing Oxa with AOM. MyD88 KO mice were more 
resistant than WT mice to either model, with decreased weight loss and tumor numbers. 
Tumor formation was found to be dependent on IL-6, and the role of MyD88 appeared to 
be hematopoietic intrinsic by BM chimeric studies (105).  
 Although epithelial IKKβ is protective against colitis as previously discussed, it 
actually harbors tumor promoting capabilities. Under the AOM+DSS model of colitis-
induced colon cancer, epithelial specific IKKβ KO mice develop fewer tumors, although 
tumor size is not affected. This decrease in tumor number was associated with increased 
apoptosis and pro-apoptotic factors, and decreased anti-apoptotic Bcl-xL. The tumor 
promoting role of IKKβ was further identified in myeloid cells, such as macrophages and 
neutrophils, using a different cell-specific conditional KO mouse. When treated with 
AOM+DSS, these mice had fewer tumors, and a higher percentage of smaller tumors 
than WT mice. Although levels of apoptosis were not affected in these mice, there were 
reduced levels of proliferation and inflammatory molecules (100). So while epithelial 
IKKβ prevents tumor cell apoptosis, myeloid IKKβ promotes tumor cell growth.  
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 As discussed earlier, the TIR negative regulator SIGIRR demonstrates that 
hyperactive NF-κB signaling promotes colitis. SIGIRR KO mice are also more 
susceptible to AOM+DSS colon cancer, exhibiting increased tumor incidence, tumor 
number, and tumor size. These mice had increased tumor cell proliferation and 
expression of inflammatory molecules (101). Therefore, uncontrolled NF-κB activation 
via SIGIRR KO causes an exacerbated inflammatory response resulting in death with 
colitis, and increased tumor burden with colon cancer.  
 Similar to the protective role of MyD88 in colitis, Salcedo et al demonstrated that 
MyD88 is also protective from AOM+DSS induced colon cancer. MyD88 KO mice 
exhibited increased bleeding, diarrhea, inflammation, ulcers, polyps, and even squamous 
metaplasia, while hematocrit and colon length were decreased. Although KO mice had 
decreased proliferation and DNA repair molecules, there was also increased apoptosis, 
angiogenesis, and inflammation. The tumors in MyD88 KO mice even progressed into 
adenocarcinomas over time. To determine which upstream receptor was involved, IL1R, 
IL-18, and IL18R KO mice were also treated with AOM+DSS. Although IL1R KO mice 
were phenotypically similar to WT controls, IL-18 and IL18R KO mice demonstrated a 
similar phenotype to MyD88 KO mice with increased bleeding and polyp numbers. 
Additionally, IL-18 KO mice are also more susceptible to DSS-colitis, with increased 
bleeding, diarrhea, ulceration, and colonic shortening (97). Therefore, MyD88 is 
protective in both colitis and colon cancer, at least in part due to IL-18 signaling. 
However, the precise role of TLRs was not investigated in this model.  
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TLRs in colitis and cancer  
TLRs are expressed highly on antigen presenting cells, such as DCs, B cells, and 
macrophages, with lower expression on epithelial, paneth, and T cells. Within the gut, 
leukocytes are located in the lamina propria, just under the epithelial lining. Although 
TLR2 and TLR4 are expressed throughout the small and large intestines, higher 
expression was found in the colon. TLR2 was more dominant in the proximal colon, 
while TLR4 was greater in the distal colon. DSS-colitis upregulated both TLRs, but the 
expression patterns remained similar (106). Patients with ulcerative colitis and Crohn’s 
disease also have increased levels of intestinal TLR2 and TLR4 (107). Rakoff-Nahoum 
subjected TLR2 and TLR4 KO mice to DSS-colitis, and found that both KO mice had 
increased weight loss and mortality (92). TLR2 and 4 may therefore be protective against 
colitis, and their expression is upregulated in order to ameliorate disease.  
In sporadic human colorectal cancer, TLR2 mRNA is increased in tumor tissue, 
while TLR4 expression does not differ (107). In another study however, TLR4 protein 
was increased in tumor tissue from colitis-associated cancer samples (108). Fukata and 
colleagues characterized the expression level of various TLRs in the murine AOM+DSS 
model. TLR2, 3, 4, 5, and 9 were all increased upon treatment in both tumor tissue and 
nondysplastic surrounding mucosa. While most TLRs had higher expression in the 
surrounding mucosa than the tumor, only TLR4 was higher within the tumor. Treating 
TLR4 KO mice with AOM+DSS demonstrated the tumor promoting role of TLR4. KO 
mice had decreased tumor incidence, tumor number, tumor size, and area affected. TLR4 
was found to induce Cox2 expression, which induced PGE2, amphiregulin, and EGF, thus 
leading to increased proliferation of cancer cells (108).  
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 Contrary to Fukata’s work, Lowe et al demonstrated that TLR2 protects against 
AOM+DSS induced colon cancer. Treated TLR2 KO mice had increased weight loss, 
mortality, tumor number, tumor size, high grade dysplasia, and aberrant crypt foci. 
Expression of β-catenin, pSTAT3, and inflammatory molecules were also increased, as 
well as Th17 responses and proliferation. Apoptosis and NO production, however, were 
reduced (109). Therefore, TLR2 and TLR4 have opposing roles in colon cancer, which 
raises the question of the roles of other TLRs in colon cancer. Collectively, these data 
demonstrate that NF-κB plays both protective and promoting roles in the AOM+DSS 
model (Table II). While IL18R and TLR2 protect, TLR4 promotes. The role of other 
upstream receptors must therefore be determined in order to clarify the role of NF-κB.  
 TLRs have also been directly implicated in other cancer types. For instance, Kim 
et al demonstrated that Lewis lung carcinoma secretes versican, an extracellular matrix 
proteoglycan, which is recognized by the TLR2/6 heterodimer on macrophages. TLR 
ligation leads to macrophage activation with IL-6 and TNFα production which promoted 
metastatic tumor growth (110). In this setting, TLR2/6 signaling promotes metastasis. 
Another study by Earl et al demonstrated metastatic promotion by TLR4. MC38 murine 
colon cancer cells were injected subcapsularly into the spleen of WT and TLR4 KO mice. 
This method mimics the portal circulation of metastatic colorectal cancer cells. Although 
host TLR4 expression had no effect, TLR4 expression on MC38 cells promoted 
metastasis, as evidenced by MC38 cells treated with TLR4 siRNA (111).  
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V. Molecules and pathways implicated in cancer  
Due to the significant findings of our data and the direction of our work, we will now 
discuss molecules and pathways which will be important for understanding and 
interpreting our results. We will discuss IL-17 and IL-23, the Wnt/β-catenin pathway, 
DNA repair, and inflammasomes. We will explain the basics of each of these, and then 
go into what is known about their role in colitis and cancer.  
 
IL-17 & IL-23  
IL-17 is a cytokine which is predominately produced by proinflammatory Th17 cells. Wu 
and colleagues demonstrated that colitis caused by enterotoxigenic  Bacteroides fragilis, 
a colonic bacterium, is mediated by IL-23, STAT3, and IL-17 producing Th17 cells 
(112). Utilizing the AOM+DSS model of colitis-associated colon tumorigenesis in IL-
17A KO mice, Hyun et al demonstrated the tumor promoting role of IL-17A. KO mice 
exhibited decreased tumor number, tumor size, inflammation, proliferation, and 
proinflammatory cytokine expression (113).  
Another group used recombinant and retroviral transduction of IL-17 into tumors 
to reveal pro-tumor growth and pro-angiogenic characteristics, such as cord formation 
and vascular endothelial cell migration (114). Additionally, IL-17A promotes growth of 
the bladder cancer cell line MB49 and the melanoma cell line B16 when injected into 
mice. IL-17A was found to promote IL-6 expression, leading to STAT3 activation, and 
stimulating survival and angiogenesis, thus aiding tumor growth. Furthermore, IL-17 is 
elevated in various cancers as well as patients with ulcerative colitis (115, 116).  
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 IL-23 is a dimeric cytokine consisting of the specific p19 subunit together with 
the p40 subunit, which is also shared with IL-12. This cytokine, which is required for 
Th17 cell differentiation, is also linked to cancer. Langowski and colleagues discovered 
the tumor promoting role of IL-23 in the DMBA+TPA skin papilloma model, 
demonstrating its role in both tumor growth and incidence (117). This work was later 
verified by Teng et al, who further describe the tumor promoting and metastatic 
potentiating effects of IL-23 in MCA-induced fibrosarcoma and B16F10 melanoma 
transfer models (118). IL-23 has also been shown to play a promoting role in the T cell 
transfer model of colitis, where it suppresses Tregs while inducing Th17 accumulation 
(119).  
 Besides mouse models, a clinical role for IL-23 has also emerged. This cytokine 
is elevated in various human cancers, such melanoma, stomach, breast, lung, and head 
and neck cancer, with the highest fold induction found in ovarian and especially colon 
cancer (117). IL-23, along with its receptor IL23R, is elevated in both ulcerative colitis 
and Crohn’s Disease patients (116). Additionally, mutations within IL23R have further 
highlighted the link between this cytokine and Crohn’s disease (120). Therefore, both IL-
17 and IL-23 promote tumorigenesis and colitis.  
 
Wnt/β-catenin  
The Wnt pathway supports multiple cellular processes, such as proliferation, 
differentiation, apoptosis, cell motility, and tissue patterning (121, 122). The ligands for 
this pathway are the secreted Wnt family molecules, composed of 19 members: Wnt1, 
Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt8a, 
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Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11, and Wnt16 (121). These ligands are 
recognized by the Frizzled (Fzd) cell surface receptors together with the LRP coreceptors 
(122). The family of Fzd receptors is composed of 10 members, Fzd1-10 (123).  
 The canonical Wnt pathway is usually turned off. In this state, a cytosolic 
destruction complex exists, composed of glycogen synthase kinase 3 (GSK3), APC, 
Axin, and casein kinase Iα (CKIα). This complex phosphorylates β-catenin, causing it to 
be ubiquitinated by βTrCP and degraded by the proteasome. Upon ligation of the 
receptors with Wnt, the downstream pathway is activated. Receptor aggregates form 
which recruit disheveled (Dsh) to phosphorylate LRP. Phospho-LRP then recruits Axin, 
thus causing dissociation of the destruction complex and liberation of β-catenin. β-
catenin accumulates in the cytoplasm, and then translocates to the nucleus where it acts 
as a coactivator with the transcription factors TCF/LEF (T cell factor/lymphoid enhancer 
family) (122).  
Unlike the canonical pathway, activation of the noncanonical Wnt pathway is 
independent of β-catenin and LRP. Instead, the release of intracellular calcium activates 
the pathway, where Wnt associates with a Fzd receptor to activate Dsh, but this time 
activating the calcium sensitive kinases CamKII and PKC. Dsh can also activate small 
GTPases (Rho, Rac, Cdc42), which activate JNK, MAPK, ROCK, and AP-1. 
Importantly, the Wnt pathway is deregulated in various diseases, such as hyperactivation 
in colorectal cancer (122, 124).  
Various Fzd receptors have been associated with colon cancer. One study shows 
that Fzd1 and Fzd2 were not present in normal tissue, but were expressed at the protein 
level in poorly differentiated human colon cancer samples at the border of invasion, 
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suggesting a role for these receptors in tumor invasion (125). Another study shows that 
among the ten different Fzd receptors, Fzd3, 5, and 8 are moderately expressed, and 
Fzd4, 6, and 7 are highly expressed in human colon cancer cell lines. In particular, Fzd7 
was more consistently highly expressed in all cell lines examined, and it is also expressed 
in various primary human colon cancer samples. Furthermore, Fzd7 is able to induce Wnt 
target genes in cancer cell lines, even in the presence of APC and β-catenin mutations 
(123).  
Utilizing ethylnitrosourea to induce germline mutations, Moser and colleagues 
discovered a mouse line which developed spontaneous adenomas in both the small and 
large intestines. Since mice exhibited multiple intestinal neoplasia, they termed the 
mutated gene Min (102). Later, this gene was identified as APC, an important molecule 
in the Wnt signaling pathway, and these mice are now known as APC
Min
 mice. 
Furthermore, Wnt ligands themselves are also associated with colon cancer. Although the 
expression of Wnt1, 4, 5b, 7a, 10b, and 11 were unaltered between normal and colon 
cancer, Wnt2, and to a lesser extent Wnt5a, were both upregulated in human colon cancer 
samples compared to normal adjacent tissue (125).  
Macrophages in particular are important for linking Wnt pathway activation and 
cancer. Macrophages secrete IL-1β via Stat1 activation, which activates the Wnt pathway 
in human colon cancer cells, inducing their growth. This pathway can be inhibited with 
vitamin D3, which attenuates Stat1 activation (126). Activated macrophages can also 
secrete TNFα, which inhibits GSK3β and thus activates the Wnt/β-catenin pathway in 
gastric tumor cells (127). Conversely, Ojalvo and colleagues showed that TAMs, which 
promote murine mammary tumor cell invasion, have increased Wnt pathway molecules. 
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Multiple Fzd receptors and Wnt ligands were increased, as well as TCF7, Axin, and 
LRP5 (121). Similarly, Pukrop et al demonstrated that macrophages cocultured with 
breast cancer cells upregulate Wnt5a, leading to increased MMP7 and enhanced 
invasiveness of tumor cells (128).  
Murine macrophages infected with Mycobacterium tuberculosis upregulated Fzd1 
expression in a manner dependent on TLRs, MyD88, and NF-κB. When activated with 
the Wnt3a ligand, these macrophages became anti-inflammatory with reduced TNF 
release (129). This study therefore links together the TLR and Wnt pathways. 
Collectively, these data demonstrate the strong link between increased Wnt signaling and 
cancer, with a promoting role of macrophages in particular.  
 
DNA Repair  
Many intrinsic and extrinsic insults exist which cause DNA damage. Intrinsic factors 
include alkylation, oxidation, hydrolysis, and mismatched DNA bases. Extrinsic factors 
include ultraviolet radiation, ionizing radiation, and chemical agents. Such DNA damage 
can cause genetic mutations, leading to senescence, apoptosis, and increased 
susceptibility to cancer, neurological disorders, and immunodeficiency. Organisms have 
therefore evolved a series of checkpoints to recognize DNA damage, and multiple DNA-
damage repair pathways to correct the problems (130).  
 Six DNA repair pathways exist which correct different types of DNA damage: 1. 
Mismatch repair (MMR), 2. Base excision repair (BER), 3. Direct reversal, 4. Non-
homologous end joining, 5. Homologous recombination, and 6. Nucleotide excision 
repair (130). However, only the first two pathways are associated with colon cancer (130-
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132). The MMR pathway repairs insertion/deletion loops and base mismatches which 
usually occur during DNA replication (130, 133). It can also correct base modifications 
caused by oxidizing, alkylating, and methylating agents, among others. In particular, the 
MMR pathway repairs O
6
 methylguanine-containing mismatches, which are recognized 
by the MSH heterodimer (133). The BER pathway consists of two sub pathways, the 
short- and long-patch BER. These pathways fix both short (1 nucleotide) and long (2-13 
nucleotides) base damage, respectively (130).  
 The MMR pathway has been associated with colon cancer in both mice and 
humans. MLH1, MLH3, MSH2, MSH3, and MSH6 KO mice all develop spontaneous 
intestinal tumors (130). Additionally, hereditary non-polyposis colorectal cancer 
(HNPCC), or Lynch syndrome, has been associated with mutations in MLH1 and MSH2 
at high frequencies (70-80%) (130, 131, 134). Mutations in MSH6 have been found in 
10% of cases, and to a lesser extent, mutations have also been found in MLH3, PMS1, 
PMS2, and EXO1 (130, 131). Biallelic MLH1 inactivation has further been associated 
with sporadic colorectal tumors (130, 133). Microsatellite instability (MSI) also occurs in 
colon cancer, which is associated highly with hypermethylation of the MLH1 promoter, 
loss of MLH1 protein, and mutations in various MMR genes (135). Furthermore, 
mismatch repair-deficiency syndrome, which causes multiple malignancies including 
colon cancer, is associated with inherited biallelic dysfunction of MMR genes (131).  
 The BER pathway has also been associated with both human and murine colon 
cancer. The autosomal recessive disorder, MYH-associated polyposis (MAP), is 
correlated with biallelic mutations in the MYH gene and is associated with colonic 
adenomas and carcinomas. Mutations within the adenomatous polyposis coli (APC) gene 
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are usually found in MAP tumors as a result of loss of MYH function. MYH KO mice 
even develop spontaneous intestinal tumors (130). Furthermore, although AAG KO mice 
do not develop spontaneous tumors, they are more susceptible to the AOM+DSS colon 
tumorigenesis model, harboring more tumors, worse pathology, and more severely 
shortened colons (132). This work was later extended to show that ALKBH2 and 
ALKBH3, DNA glycosylases which recognize etheno-base lesions similar to AAG, also 
confer increased susceptibility to the AOM+DSS model (136).  
 
Inflammasomes  
Inflammasomes are multi-protein complexes located within the cytosol. A few 
inflammasomes have been described, the majority of which contain NOD-like receptors 
(NLRs): NLRP1, NLRP3, NLRP6, and NLRC4. Another inflammasome has been 
identified which contains the HIN200 molecule absent in melanoma 2 (AIM2). Murine 
NLRP1 and NLRC4 contain caspase recruitment domains (CARDs) which bind various 
caspases, such as Casp1 and Casp11. NLRP3 and NLRP6, however, lack these CARD 
domains, yet contain pryin (PYD) domains. These NLRs require an adaptor protein, 
ASC, which itself has both a PYD and CARD domain. After ASC binding, these NLRs 
can then recruit caspase via the CARD domain of ASC (137).  
 Caspase recruitment is essential for inflammasome effector mechanisms. Caspase 
activation leads to the cleavage of proIL-1β and proIL-18 into the mature IL-1β and IL-
18 cytokines, which are then secreted. IL-1β promotes antibody production, B cell 
proliferation, T cell survival and polarization (Th1, Th2, and Th17), leukocyte migration, 
and fever. IL-18 stimulates IL-4 and IL-5 production which can promote Th2 responses. 
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It can also synergize with IL-12 to induce T cell and NK production of IFNγ to promote 
Th1 polarization. IL-18 can also facilitate IL-17 production and promote Th17 responses 
(137).  
 Pyroptosis, a method of proinflammatory cell death via caspase 1 activation, is 
another effector mechanism of inflammasomes. When a host cell is infected by a virus or 
intracellular bacterium, cell death is a way to prevent pathogen propagation. 
Inflammasomes can be triggered by both PAMPs and DAMPs, either directly or 
indirectly. The exact molecular pattern recognized depends on which inflammasome is 
activated. Hyaluronan, amyloid β fibrils, uric acid crystals, ATP, bacterial PrgJ basal 
bodies, flagellin, and pathogenic genomic material have all been identified as ligands of 
inflammasomes. In the case of ATP, a microbial protease cleaves host mitogen-activated 
protein kinase kinases (MKKs), and the resulting inhibition of p38 then triggers ATP 
release from the cell. ATP is then recognized by the surface receptor P2X7, inducing 
proteasome activation and calcium fluxes, which then activate NLRP1 (137).  
 Various data have proven a protective role for the inflammasomes in colitis and 
colitis-induced colon cancer (Table II). Casp1 KO mice are extremely susceptible to 
DSS-induced colitis, demonstrating its protective role. ASC KO mice had a milder 
phenotype, while Casp12 KO mice showed no phenotype compared to WT controls. 
However, Casp12 KO mice were more susceptible to AOM+DSS colon cancer. 
Interestingly, exogenous IL-18 treatment, which bypasses the requirement for caspases, 
rescues Casp1 KO mice from colitis (138). Besides the caspases, NLRP genes have also 
proven to play a role. NLRP12 protects against both DSS-colitis and AOM+DSS colon 
cancer. This was shown to be due to regulation of the noncanonical NF-B pathway, and 
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NLRP12 expression was important in both hematopoietic and non-hematopoietic 
compartments, although the latter was more important for tumorigenesis (139, 140).  
 Besides NLRP12, many studies have also demonstrated a role for NLRP3 in 
cancer. Ghiringhelli et al found that tumor cells release ATP, which is recognized by the 
P2X7 receptor on DCs and triggers the NLRP3/Casp1 inflammasome to produce IL-1β, 
which activates cytotoxic T lymphocytes to produce IFNγ (141). Zaki et al found that 
NLRP3, ASC, and Casp1 KO mice are all more susceptible to DSS-colitis than WT mice. 
This protection was dependent on IL-18 and nonhematopoietic expression of NLRP3 
(142). A couple weeks later, another study by Allen et al demonstrated that NLRP3, 
ASC, and Casp1 KO mice are all susceptible to both acute and chronic DSS-induced 
colitis, as well as AOM+DSS colon cancer. The colonic tumors were further associated 
with reduced levels of IL-1β and IL-18, and NLRP3 expression in hematopoietic cells 
was important for protection against tumors. However, NLRC4 KO mice had similar 
resistance to colon cancer as WT mice (143).  
 The previous data suggests that IL-18 in particular, through inflammasome 
activation, is important for protection against colitis and inflammation-induced colon 
cancer. A couple of months after the previous papers were published, Zaki et al came out 
with another article which confirmed Allen’s data on the protective role of NLRP3, ASC, 
and Casp1 in AOM+DSS colon cancer. Furthermore, although levels of IL-1β were 
unaltered in these mice, IL-18 was significantly decreased. Utilizing IL-18 KO mice 
demonstrated the protective role of this cytokine in AOM+DSS colon cancer. IL-18 
administration was also able to rescue Casp1 KO mice. Moreover, reduced IL-18 was 
associated with decreased IFNγ, and thus diminished Stat1 activation in both epithelial 
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and immune cells (144). However, overproduction of IL-18 can also exacerbate colitis 
with increased macrophage infiltration (145). Therefore, the dose of IL-18 is extremely 
important for disease outcome.  
 
VI. Colitis and colon cancer  
Since we utilize mouse models of colitis and colon cancer, we will next describe the 
clinical aspects of these diseases to help convey the translational importance of our work.  
 
Inflammatory Bowel Diseases  
Inflammatory Bowel Diseases (IBD) encompass ulcerative colitis and Crohn’s disease. 
Although the etiology for either disease is unknown, some common themes have been 
observed. Crohn’s disease is associated with defective intracellular bacterial processing, 
while ulcerative colitis is associated with epithelial barrier integrity. In Crohn’s disease, 
71 susceptibility genes have been discovered, many of which are linked to the immune 
system, such as the intracellular pathogen recognition receptor NOD2. In ulcerative 
colitis, 47 genes have been determined, some of which are important for immunity and 
epithelial barrier function. Furthermore, 28 genes are linked to both diseases, such as 
various immune genes and the IL-17/IL-23 axis. Moreover, 51 of these IBD susceptibility 
genes are associated with 23 other diseases, both immune- and nonimmune-mediated: 
asthma, alopecia, dermatitis, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, 
vitiligo, and diabetes (146).  
Chronic IBD is associated with abdominal pain, which can be either somatic or 
visceral, and can even persist during remission. Four categories of pain are seen in IBD 
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patients: inflammation, bacterial overgrowth, surgical complications, and neurobiological 
processes. Even common medications used to treat the inflammation can cause pain, 
which itself can become disabling (147). A more severe concern in IBD patients is the 
increased risk of colorectal cancer. It presents at a younger age, accounts for 10-15% of 
IBD deaths, and is due to both genetic and acquired factors. The potential risk factors are 
severity of inflammation, duration and extent of colitis, gender, age at diagnosis, 
coexistent primary sclerosing cholangitis, and family history of sporadic colon cancer. 
Therefore, routine colonoscopy surveillance is performed 8 to 10 years after IBD 
diagnosis (148). In order to develop IBD therapies, the etiological understanding of these 
diseases must be elucidated.  
 
Colon cancer  
There are two forms of colon cancer, sporadic and inherited, where benign polyps may 
form throughout the length of the colon. Although the majority of these will remain 
benign, a few will progress with age to adenomas, or even carcinomas. There are various 
colon cancer syndromes: familial adenomatous polyposis (FAP), hereditary nonpolyposis 
colorectal cancer (HNPCC), Gardner syndrome, Turcot’s syndrome, attenuated 
adenomatous polyposis coli, Peutz-Jeghers syndrome, Cowden disease, Juvenile 
polyposis syndrome, and MYH-associated polyposis. The majority of colon cancers are 
associated with other cancer types, such as renal, ovarian, hepatobiliary, endometrial, and 
gastric, among others. Some of the sporadic colon cancers are associated with chronic 
inflammatory conditions. For instance, patients with ulcerative colitis are 10 times more 
likely to develop colon cancer (124).  
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 Inherited colon cancer syndromes have facilitated the identification of genes 
commonly mutated within this disease. Two pathways are highly mutated: the Wnt/β-
catenin and DNA repair pathways. APC is the most commonly mutated gene within the 
Wnt pathway, while β-catenin, Axin1, Axin2, and TCF4 have also been found to have 
mutations. The various DNA repair genes which are mutated include MLH1, MSH2, 
MSH6, MYH, and PMS2. Another category of mutations occur within Ras small-G 
proteins downstream of growth factor receptors, such as KRAS and NRAS. Another 
common phenomenon in colon cancers is the presence of microsatellite instability, with 
high and low frequencies being characterized. Unfortunately, 150,000 Americans are 
diagnosed with colon cancer annually, and a third of these patients will die from the 
disease (124). As with other cancer types, treatments are heavily sought after.  
 
VII. Outline of this thesis dissertation  
The following chapter will detail all experimental methods used. Chapter 3 contains data 
elucidating gp93 as the Drosophila ortholog of mammalian gp96. We will show that 
gp93 is capable of rescuing gp96 client protein expression. Gp93 interacts with TLR9 and 
can form a dimer with gp96. We demonstrate that although gp93 is incapable of forming 
disulphide bond dependent C terminal dimerization, this ability is not required for 
chaperone function. We further elucidate various amino acids which are important for 
function, helping to characterize the gp96 CBD.  
 The second half of the following chapter focuses on characterization of the 
Drosophila CNPY family, focusing on CNPYb in particular. We determine that CNPYb 
is a TLR-specific cochaperone. We also demonstrate that both CNPYa and CNPYb can 
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rescue β2 expression without gp93. We further reveal that both gp96 and gp93 are able to 
physically interact with both CNPY3 and CNPYb. Upon scrutiny of the CNPYb amino 
acid sequence, we determine that disulfide bonds between cysteine residues are important 
for function. Unfortunately, we are not able to determine whether or not gp93, CNPYa, or 
CNPYb play a role in chaperoning endogenous Drosophila Toll.  
 Chapter 4 of this thesis moves to determine the role of macrophage-specific gp96 
in colitis and inflammation-associated colon tumorigenesis. We first demonstrate a 
promoting role in colitis, characterized by differences in pathology, colon length, stool 
consistency, and cytokine expression. We also show a promoting role in colon 
tumorigenesis, illustrated by differences in pathology, tumor burden, cytokine expression, 
CD4
+
 IFNγ+ cells, and Wnt signaling. In particular, differences in IL-17, IL-23, and 
TNFα are found. We also describe huge differences in β-catenin mutations, yet no 
differences in DNA repair between WT and KO mice. Finally, we determine that the 
phenotype seen is indeed hematopoietic intrinsic.  
 At the end of each results chapter is a discussion section where we examine the 
data, make conclusions in relation to the literature, and debate the significance. The final 
chapter of this thesis starts with a summary of all the data and their conclusions. We then 
discuss future directions in sight of the gathered data, and bring the thesis to a conclusion.  
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Table I: Comparison of mammalian and Drosophila protein families.   
 
Mammals Drosophila 
TLRs/Toll 
TLR1, TLR2, TLR3, 
TLR4, TLR5, TLR6, 
TLR7, TLR8, TLR9, 
TLR10, TLR11, 
TLR12, TLR13 
Toll, Toll-2, Toll-3, 
Toll-4, Toll-5, Toll-
6, Toll-7, Toll-8, 
Toll-9 
Alpha 
Integrins 
α1, α2, α3, α4, α5, 
α6, α7, α8, α9, α10, 
α11, αIIb, αD, αE, 
αL, αM, αV, αX 
αPS1, αPS2, αPS3, 
αPS4, αPS5 
Beta 
Integrins 
β1, β2, β3, β4, β5, 
β6, β7, β8 
βPS, βν 
CNPYs 
CNPY1, CNPY2, 
CNPY3*, CNPY4 
CNPYa, CNPYb 
Underlined genes represent identified gp96 clients. * indicates identified gp96 
cochaperone.  
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Table II: Literature review of DSS-colitis and AOM+DSS colon cancer.  
Gene Expression DSS AOM+DSS Reference 
SIGIRR 
Global Protects Protects Xiao 
IEC Protects Protects Xiao 
IKKβ 
IEC Protects Promotes Greten 
Myeloid Unknown Promotes Greten 
MyD88 
Global Protects Protects 
Araki, Rakoff-Nahoum, 
Salcedo 
B, T, DC, 
Mac 
Protects Unknown Kirkland 
Epithelial No effect Unknown Kirkland 
TLR2 Global Protects Protects Rakoff-Nahoum, Lowe 
TLR4 Global Protects Promotes Rakoff-Nahoum, Fukata 
IL1R Global Unknown No effect Salcedo 
IL-17A Global Unknown Promotes Hyun 
IL-18 Global Unknown Protects Salcedo, Zaki  
IL18R Global Unknown Protects Salcedo 
NLRP3 Global Protects Protects Allen, Zaki 
NLRP12 Global Protects Protects Allen, Zaki 
NLRC4 Global Unknown No effect Allen 
ASC Global Protects Protects Dupaul-Chicoine, Zaki, Allen 
Casp1 Global Protects Protects Dupaul-Chicoine, Zaki, Allen 
Casp12 Global No effect Protects Dupaul-Chicoine, Zaki 
IEC, intestinal epithelial cell. B, B cell. T, T cell. DC, dendritic cell. Mac, macrophage.  
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Chapter 2 
 
Materials and Methods 
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Cell lines: Phoenix Eco cells were cultured in DMEM medium (Sigma-Aldrich) 
supplemented with 10% FBS (Atlas Biologicals), 100U/ml Penicillin and 100μg/ml 
Streptomycin (Gibco). 14.GFP (WT) and gp96 mutant E4.126 (KO) murine pre-B cells 
were obtained from Randow and Seed (Harvard University) (3). Cells were maintained in 
RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% FBS, 100U/ml Penicillin 
and 100μg/ml Streptomycin, and 0.055 mM 2-mercaptoethanol (Life Technologies). The 
above cells were all cultured at 37°C with 5% CO2 in a humidified incubator. 
Drosophila S2 and S2* cells were gifts from Dr. Brenton Graveley (UCHC) and 
Dr. Neal Silverman (UMASS), respectively. S2 cells were cultured in Express Five SFM 
medium (Life Technologies) supplemented with 18mM L-Glutamine (Gibco), 100U/ml 
Penicillin and 100μg/ml Streptomycin. These cells were cultured at 27°C while gently 
shaking. S2* cells were cultured in Schneider's Drosophila Medium (PromoCell) 
supplemented with 10% FBS, 20U/ml Penicillin, 20μg/ml Streptomycin, 1% GlutaMax 
(Gibco), and 12.33mM L-Glutamine. These cells were cultured at 27°C without shaking. 
All cells were cultured using sterile technique.  
 
Sequence Alignment & Conservation Mapping: Murine (NP_035761) and Canine 
(NP_001003327) gp96 were blasted on the National Center for Biotechnology 
Information (NCBI) database to search for genes with high sequence homology. We 
identified the gene gp93 (NP_651601) from Drosophila melanogaster with unknown 
function. ClusterW was used to align all three gene sequences (149). ConSurf and PyMol 
(http://www/pymol.org/) were then used to map sequence conservation among the genes 
onto the molecular surface of the structure of canine gp96 (PDB ID:2O1U) (150).  
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Cloning Constructs: mRNA was isolated from S2 cells and reverse transcribed into 
cDNA in order to amplify gp93, CNPYa, and CNPYb by PCR. Gp93 was cloned into the 
pGEM-T Easy vector (Promega) and then subcloned into the MigR1 retrovector 
expressing a GFP reporter. WT gp93 was then used to amplify gp93
Flag
 by PCR using a 
different reverse primer. Both constructs were engineered with a KDEL instead of a 
HDEL ER retention signal after the FLAG epitope (DYKDDDDK) to ensure proper 
localization in a murine system. CNPYa and CNPYb were cloned directly into the MigR1 
retrovector. Both constructs were engineered with a C-terminal Myc tag 
(EQKLISEEDL). Refer to Table III for gene accession numbers and Table IV for cloning 
primer sequences.  
 
Site-Directed Mutagenesis: All gp93 mutants were PCR amplified from gp93
Flag
 with 
the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) per the manufacturer’s 
protocol. All CNPYb mutants were PCR amplified from CNPYb myc using the same kit. 
All primers were designed using Stratagene’s online primer design program to 
incorporate the mutations. Refer to Table III for gene accession numbers and Table IV 
for primer sequences.  
 
Virus Production and Transduction:  Phoenix Eco cells were transfected with 
ecotropic retrovectors using Lipofectamine 2000 (Invitrogen). Virus was collected 2 days 
later and used to transduce 2 X 10
5
 E4.126 cells with the addition of hexadimethrine 
bromide (Sigma-Aldrich). Cells were then centrifuged at 1900g, 32°C for 1.5hrs to 
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achieve viral transduction. The GFP-reporter of the retrovector was used to determine 
transduction efficiency by FACS, and two to three rounds of transduction was performed 
to obtain high transduction efficiency.  
 
FACS: Single cell suspensions were obtained and washed in PBS, and then washed in 
FACS Buffer (1x PBS, 2% FBS, and 0.9g/L sodium azide). Cells were then blocked with 
FACS Buffer containing serum and an FcR blocking antibody. Cells were incubated with 
primary antibody, washed, and then incubated with fluorochrome-labeled secondary 
antibody. Cells were washed, and then stained with propidium iodide to exclude dead 
cells. For intracellular staining, cells were first fixed with 4% formaldehyde and then 
permeabolized with methanol. Cells were then stained as above, except without FcR 
blocking antibody or propidium iodide. Cells were acquired on a FACS Calibur (BD 
Biosciences) using Cell Quest software, and data was analyzed using FlowJo software.  
 
Western Blot: Single cell suspensions were washed with PBS and then lysed using 
radioimmunoprecipitation assay (RIPA) lysis buffer (150 mM NaCl, 0.01 M sodium 
phosphate pH 7.2, 1% Nonidet P-40, 2 mM EDTA, 0.1% SDS, and 1% sodium 
deoxycholate). Protein concentration was quantified by Bradford Protein Assay (Bio-
Rad) and read with a microplate reader. Equal amounts of total cell lysate were denatured 
with the addition of SDS loading buffer and 0.1 M DTT, and boiled for 5 minutes. 
Denatured protein was then resolved on 10% SDS-PAGE and transferred onto a 
polyvinylidene difluoride membrane. Membranes were blocked with 5% milk-
PBS/Tween for 2hrs at RT, and then incubated with primary antibody diluted in 5% milk-
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PBS/Tween at 4°C overnight. Membranes were washed and then incubated with the 
appropriate HRP-conjugated secondary antibody diluted in 5% milk-PBS/Tween for up 
to 2hrs at RT. Membranes were then washed and developed with chemiluminescent 
substrate (Pierce Chemical) and exposed to film.  
 
Immunoprecipitation: Single cell suspensions were washed with PBS, and then treated 
with or without 0.1 mg/ml dithiobis-succinimidyl propionate (Thermo Scientific) at RT 
for 30 minutes, and then lysed with RIPA buffer. 1200ug of lysate was precleared with 
Protein G beads (GenScript) and then removed and incubated with HA, Flag, or isotype 
control antibodies at 4°C for 1hr. Lysate-Ab mixtures were then incubated with fresh 
Protein G beads at 4°C overnight while rotating. RIPA lysis buffer was used to 
vigorously wash the beads, and then protein was eluted by boiling in SDS-loading buffer 
with 0.1M DTT. Eluted protein was then resolved on 10% SDS-PAGE and 
immunoblotted as above.  
 
RNAi and Toll Signaling: Primers were designed to specifically recognize the gene of 
interest and span approximately 600-800bp. T7 promoter sites were designed within the 
primers to flank the gene sequence. The negative control RNAi construct was designed to 
amplify the MigR1 retrovector without recognizing any DNA sequences in Drosophila. 
Refer to Table V for RNAi primer sequences. CNPYa, CNPYb, and Toll were first 
amplified via PCR from S2 cDNA using the RNAi primers, and cloned into the pGEM-T 
Easy vector (Promega) to facilitate future production of RNAi. These vectors were then 
used as templates, along with the MigR1 and gp93-MigR1 vectors, for PCR amplification 
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of RNAi constructs. The PCR products were then purified and in vitro transcribed to 
RNA using T7 polymerase and a kit from Epicentre. The sense and anti-sense RNA 
strands were then annealed together at 75°C for 15 minutes, and then allowed to cool to 
RT. Annealed RNA was treated with DNAse at 37°C for 15 minutes to digest remaining 
DNA, and then purified using Centri Spin-20 columns (Princeton Separations).   
 S2* cells were cultured at a density of one million cells per ml. The following 
day, two million cells were seeded in 3ml of medium in a 6-well dish. The next day the 
cells were treated with 6μg of annealed RNAi mixed with 125mM CaCl2 in BBS buffer. 
The mixture was vortexed and incubated for 15 minutes before being added drop-wise to 
the cells. The plates were gently swirled to mix, and left over night. The following day, 
cells were split to one million cells per ml to get rid of CaCl2, and then returned to 
culture. An aliquot of cells was taken at day four to isolate RNA for determination of 
knockdown efficiency via qRT-PCR (described below).  
RNAi knockdown cells were treated with 1μM 20-hydroxyecdysone (Sigma) for 
24hrs on day 6 to amplify Toll signaling as previously published (151). Cells were then 
treated on day 7 with 2.4nM rSPZ (C106, gift from Dr. Neal Silverman) for 6 hours 
(152). mRNA was then collected and Drosomycin induction was analyzed via qRT-PCR.  
 
Mice: gp96
flox/flox
 (WT) and gp96
flox/flox
 LysM Cre (KO) mice were described previously 
by our lab (4). Mice were maintained at the UCHC animal facility, and then later 
transferred to the MUSC animal facility. Animal protocols were approved at both 
facilities and strictly followed.  
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DSS-Colitis: Mice were fed 3% DSS (MP Biomedical) dissolved in their drinking water 
and fed ad libitum for 5 days. One cohort of mice was euthanized at day 5, while another 
cohort received 3 days of normal drinking water and were euthanized on day 8. Weight, 
stool scores (Stool consistency: 0, well-formed stool; 1, semi-formed stool; 2, semi-
formed stool that adheres to the anus; 3, liquid stool/diarrhea. Rectal bleeding: 0, no 
blood; 1, visible blood in stool; 2, gross rectal bleeding.), and serum were collected daily. 
After euthanasia, colon length was measured and various organs were harvested. N=5 per 
group.  
 
AOM+DSS Colorectal Cancer: Mice received one i.p. injection of 12.5mg/kg AOM 
(Sigma-Aldrich) on day 1. Two cycles of 2.5% DSS were given on weeks 2 and 5 for five 
days each, and a third cycle of 2% DSS was given on week 8 for four days. Body weight 
was recorded weekly and serum was collected every two weeks. Mice were euthanized at 
week 20, or earlier if severely moribund. Various organs were harvested after euthanasia 
for histology, RNA collection, or single cell suspensions. Colons were washed, cut 
longitudinally, and fixed in 10% paraformaldehyde overnight. Colons were then stained 
with 0.2% methylene blue (Sigma) to aid tumor visualization. A dissecting microscope 
was used to count and measure tumors. Colons were then frozen in OCT as Swiss rolls. 
N=10-17 per group.  
 
Bone Marrow Transplantation: C57BL/6 WT mice were lethally irradiated with a 
cesium irradiator. The mice received two doses of 550 cGy each, four hours apart, for a 
total dose of 1,100cGy. Mice were then reconstituted 24hrs later with 2 x 10
6
 bone 
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marrow cells by iv injection in the lateral tail vein. One group of mice received WT BM 
(WT→WT), while another group received KO BM (KO→WT). After 12 weeks, mice 
underwent the above AOM+DSS study with slight modification: DSS was administered 
on weeks 2, 8, and 11; Mice were sacrificed at week 16. To obtain BM cells, the femurs 
and tibias of mice were flushed with PBS and then lysed of red blood cells with ACK 
lysis buffer. Cells were washed and resuspended in PBS to a final concentration of 10
7
 
cells per ml. Cells were maintained under sterile conditions.  
 
Histology: Tissue was harvested and fixed overnight in 4% formalin, switched to 30% 
sucrose-PBS overnight, and then frozen in OCT medium and stored at -80°C. A Shandon 
Cryotome was used to cut 5μm sections which were mounted on charged slides. H&E 
staining was performed, and slides were scored blindly by a pathologist. Some tissue was 
also paraffin embedded for IHC.   
 
Immunohistochemistry: Paraffin embedded tissue was cut at 5μm and mounted onto 
charged slides. Slides were incubated at 55°C for 30 minutes to remove paraffin. Slides 
were cleared in xylenes, and then rehydrated in a series of ethanol, water, and then PBS. 
20μg/ml proteinase K was used for antigen retrieval, and then slides were washed. 
Endogenous peroxidase activity was quenched with 0.3% H2O2 with 0.3% normal goat 
serum diluted in PBS. After washing, slides were blocked with 10% goat serum 2% BSA 
diluted in PBS for 2hrs. Samples were stained with rat IgG2b isotype control or F4/80 Ab 
(Santa Cruz) overnight at 4°C.  Tissue was again washed and then incubated with 2% 
goat serum and biotinylated anti-rat Ab diluted in PBS (Peroxidase rat IgG Vectastain 
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ABC kit). Slides were washed, and then incubated in streptavidin Ab diluted in PBS. 
Samples were washed and then developed with DAB substrate kit (Vector Labs). 
Hematoxylin was used to counterstain the nucleus, which were then washed and 
dehydrated in a series of ethanol and xylenes. Slides were then mounted and analyzed 
under a microscope.  
 
Lamina Propria Isolation: Colon and small intestine were removed, flushed with PBS, 
and Peyers Patches were cut out. The intestines were cut longitudinally, and then into 
1cm pieces. Tissue was washed trice in cold Hank’s Balanced Salt Solution (HBSS) with 
2% FBS and vortexed for 15 seconds to aid removal of the mucus layer. Tissue was 
incubated in HBSS + 5% FBS + 1μM DTT and agitated at 100rpm at 37°C for 20mins in 
a bacterial shaker, and then vortexed. Samples were then incubated in 1.3mM EDTA 
diluted in PBS and spun at again at 37°C for 20-30 minutes, vortexed, and then this was 
repeated to remove epithelium. HBSS 2% FBS was used to wash tissue twice, and then 
RPMI for a final wash, vortexing after each. Tissue was cut further into smaller pieces 
and then spun as before with collagenase IV and 0.1mg/ml DNAse1 + 5% FBS diluted in 
RPMI for 20 minutes. The samples were then passed through a 19g syringe and a cell 
strainer to break apart the remaining tissue, and then the solution was washed with RPMI. 
This preparation was used as total lamina propria isolates to analyze myeloid cells. To 
enrich for lymphocytes, percoll centrifugation was used with 44% and 66% percoll in 
RPMI and centrifuged for 20 minutes at 2800rpm with the brake off. The middle layer 
was removed and washed in RPMI. A hemocytometer and Trypan blue were used to 
count live cells.  
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T Cell Stimulation: 10μg/ml anti-CD3 and 2μg/ml anti-CD28 Abs were used to coat 
plates in 0.1M sodium carbonate buffer at 4°C overnight. PBS was used to wash the 
wells, and then lymphocyte-enriched lamina propria isolates were added to the wells with 
1μg/ml anti-CD3 Ab diluted in RMPI. Cells were incubated at 37°C overnight, and then 
harvested for analysis via FACS.   
 
qRT-PCR: mRNA was harvested from both colon tissue and cells using TriZol reagent 
(Life Technologies) as per the manufacturer’s protocol. RNA was quantified with a 
nanodrop, and then reverse transcribed into cDNA using Superscript II H. Reverse 
Transcriptase (Invitrogen). For qRT-PCR, 5ng of RNA was used per reaction. cDNA and 
the appropriate primers were mixed with SYBR Green supermix and the reactions were 
run on a BioRad iCycler. Microsoft Excel was used for data analysis using the dCT 
method. β-actin and Rp49 were used as internal controls for murine and Drosophila qRT-
PCR reactions, respectively. Plots depict fold change in mRNA. For a list of primer 
sequences, refer to Tables VI (Drosophila) and VII (murine).  
 
Gene Sequencing: Colon cDNA was used as a template to amplify exon 3 of the β-
catenin gene via PCR. PCR products were purified with Qiagen kits and then sent to 
Genewiz for sequencing. Vector NTI software (Invitrogen) was used to align sequencing 
results, and original chromatograms were analyzed to determine mutations. Primers were 
based off of the literature (100).  
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Statistical Analysis: All results are shown as mean ± standard error (SEM) or standard 
deviation (SD) as indicated in figure legends. Student’s T test was performed to 
determine significance. All experiments were performed at least twice to confirm 
reproducibility of the results. *p<0.05, **p<0.005   
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Table III: Gene accession numbers.  
 
 
NCBI UniProt Gene 
gp93 NM_143344.2 Q9VAY2 CG5520 
gp96 NM_011631.1 P08113 Hsp90b1 
CNPYa NM_136703 Q7JXF7 CG12918-RA 
CNPYb NM_140832 Q9VVW7 CG11577-RA 
CNPY3 NM_028065 Q9DAU1 CT030702.1 
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Table IV: List of cloning primer sequences.  
 
Primer Sequence Species 
β-catenin1 F gctgacctgatggagttgga Mouse 
β-catenin1 R gctacttgctcttgcgtgaa Mouse 
CNPYa Not1 F tagcggccgcgccaccatgctgacgaaggcgcttatc Drosophila 
CNPYa Myc Not1 R 
tagcggccgcctacagttcatctttcagatcctcttctgagatgagtttttgttcg
ccatcaaagtcatactcctc Drosophila 
CNPYb Not1 F tagcggccgcgccaccatgctcctcaaaagactgcct Drosophila 
CNPYb Myc Not1 R 
tagcggccgctcacagctcatccttcagatcctcttctgagatgagtttttgttc
gtcgcccttggctttttccct Drosophila 
CNPYb C36A F tcgctacgcaaaccgcgccgaagcctgcaaaatc Drosophila 
CNPYb C36A R gattttgcaggcttcggcgcggtttgcgtagcga Drosophila 
CNPYb C39A F aaccgctgcgaagccgccaaaatcctggccac Drosophila 
CNPYb C39A R gtggccaggattttggcggcttcgcagcggtt Drosophila 
CNPYb C92A F ccctggagaacgtggccgagcgagtgttgg Drosophila 
CNPYb C92A R ccaacactcgctcggccacgttctccaggg Drosophila 
CNPYb C183A F cactgaagaagcatctcgccgaggaccatgtgctca Drosophila 
CNPYb C183A R tgagcacatggtcctcggcgagatgcttcttcagtg Drosophila 
CNPY3 Myc Not1 R 
tagcggccgcctacagttcatctttcagatcctcttctgagatgagtttttgttcg
gggctgtgtgggaggggcga Drosophila 
gp93 F  accatgaagtactttttgctggt Drosophila 
gp93 R tttacagctcgtcgtgctgct Drosophila 
gp93 Not1 F tagcggccgcgccaccatgaagtactttttgctggtg Drosophila 
gp93 Flag Not1 R 
tagcggccgcttacaattcatccttcttgtcgtcatcgtctttgtagtcctgctgct
cctcctcctc Drosophila 
gp93 A137C F ctgcacatccgcattaagtgcgacaaggagaacaagg Drosophila 
gp93 A137C R ccttgttctccttgtcgcacttaatgcggatgtgcag Drosophila 
gp93 CBD F 
tgaaggcacaagcataccagacgggcaaggacatctctacaaattactatct
caaccagaagaaaacgct Drosophila 
gp93 CBD R 
ctggtatgcttgtgccttcatgatcctctccatgttgccagaccatccatagacg
ccggccacgagggcgc Drosophila 
gp93 658-75D F ggaccggcaacatggagcgtctcaaccagaagaaaacgct Drosophila 
gp93 658-75D R agcgttttcttctggttgagacgctccatgttgccggtcc Drosophila 
gp93 2YA F cgacgatcctcagcgcaccgccgccctcaaccagaagaaaacg Drosophila 
gp93 2YA R cgttttcttctggttgagggcggcggtgcgctgaggatcgtcg Drosophila 
 F, forward primer. R, reverse primer.   
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Table V: List of Drosophila RNAi primer sequences.  
 
Primer Sequence 
CNPYa T7 F taatacgactcactataggaacgctgacccagacccactga 
CNPYa T7 R taatacgactcactataggaccggcgattcgtcgcagtag 
CNPYb T7 F taatacgactcactataggaataccggcgcagcgaactgc 
CNPYb T7 R taatacgactcactataggtaagccaatggccccaggcgaa 
gp93N T7 F taatacgactcactatagggaggccgccacaacggagac 
gp93N T7 R taatacgactcactataggggcacctcctcctcgacggt 
gp93M T7 F taatacgactcactataggaagtactcgcagttcatcaactt 
gp93M T7 R taatacgactcactataggatgtagtagatgtgctcctgctt 
MigR1 T7 F taatacgactcactataggacctaaaacagttcccgcct 
MigR1 T7 R taatacgactcactataggaggaactgcttccttcacga 
Toll T7 F taatacgactcactataggatatattcagcaacttgggcaac 
Toll T7 R taatacgactcactataggccaagtgaagttccattaattgc 
  F, forward primer. R, reverse primer.  
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Table VI: List of Drosophila qRT-PCR primer sequences.  
 
Primer Sequence 
CNPYa  F tgcagagcatcaagaaccac 
CNPYa R gtgaagctgtaaccttgggc 
CNPYb F ggaggtcacccaaatgaaga 
CNPYb R gctcacagctcctccttgtc  
Drosomycin F gcagatcaagtacttgttcgccc 
Drosomycin R cttcgcaccagcacttcagactgg 
Gp93 F actacctgagcttcattcgtgg 
Gp93 R atcctccatcacgcccaatttg  
Rp49 F agatcgtgaagaagcgcaccaag 
Rp49 R caccaggaacttcttgaatccgg 
Toll F gccggtttcacagcggcact 
Toll R gtgctccagttgcggcacca 
  F, forward primer. R, reverse primer.  
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Table VII: List of murine qRT-PCR primer sequences.  
 
 
Primer Sequence 
Aag F agcgccgctttcccgaaagatt 
Aag R gcgcccacggagttctgttcc 
ARG1 F ggtggagaccacagtctggcagt 
ARG1 R ttccccagggtctacgtctcgc 
Axin2 F tggggagcagttttgtggcagc 
Axin2 R gggcttggacttgctctgccg 
β-actin F ggtcatcactattggcaacg 
β-actin R acggatgtcaacgtcacact 
β-catenin F tccacatccttgctcgggacgt 
β-catenin R agctgcgtatgttgccacgcc 
CD11b F agagggcacggtggcagtgtga 
CD11b R ctatgatccgctggctgtgggaggc 
cMyc F tgagcccctagtgctgcat 
cMyc R agcccgactccgacctctt 
Cox2 F agccaggcagcaaatcctt 
Cox2 R attccccacggttttgaca 
Cyclin D1 F gaggttcctgttcacaatacctca 
Cyclin D1  R agaccgcccacctgcc 
F4/80 F cagccacggggctatgggatg 
F4/80 R ggtcagcaacctcgtgtccttga 
Fzd1 F gctgattgtgggcatcacatcggg 
Fzd1 R agtggccaggcttggcaggaat 
IDO1 F ggagctgcccgacgcatacag 
IDO1 R gggcagcacctttcgaacatcgt 
IL-1β F caaccaacaagtgatattctccatg 
IL-1β R gatccacactctccagctgca 
IL-6 F caggataccactcccaacagacc 
IL-6 R aagtgcatcatcgttgttcataca 
IL-12 p35 F atgtgtcaatcacgctacctcctc 
IL-12 p35 R tcccgtgtgatgtcttcatgatcg 
IL-12/23 p40 F ggaagcacggcagcagaata 
IL-12/23 p40 R aacttgagggagaagtaggaatgg 
IL-17A F atcaggacgcgcaaacatga 
IL-17A R ttggacacgctgagctttga 
IL-17F F ctgttgatgttgggacttgcc 
IL-17F R tcacagtgttatcctccagg 
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IL-22 F ttgaggtgtccaacttccagca 
IL-22 R agccggacgtctgtgttgtta 
IL-23 p19 F tgctggattgcagagcagtaa 
IL-23 p19 R gcatgcagagattccgagaga 
iNOS F agctggctcgctttgccacg 
iNOS R accctgaccatctcgggtgcg 
MLH1 F gcggtgccatgagactctccg 
MLH1 R gccagcatggccaggtcgaa 
MSH2 F cggtgcagcctaaggagacgc 
MSH2 R cttactccctgccggccccat 
MSH6 F gaggagacagaggtgcatgaggc 
MSH6 R tccccaactccactgctcgc 
p53 F aaaaccacttgatggagagtatttca 
p53 R gctcccggaacatctcgaa 
TNFα F catcttctcaaaattcgagtgacaa 
TNFα R tgggagtagacaaggtacaaccc 
  F, forward primer. R, reverse primer.  
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Rationale:  
Gp96 is implicated in sepsis, autoimmunity, and cancer (4, 23, 28, 31-33). Therefore, a 
better understanding of gp96 will prove beneficial in designing therapeutics. In order to 
gain a better understanding of gp96 biochemistry, we decided to look for a homolog in a 
simpler system. Establishing such a model will prove easier to probe, and the knowledge 
gained can then be applied to studying the mammalian system. This method has already 
proven to be beneficial in the case of HSP90, where the study of the E. coli (HtpG) and 
yeast (Hsc82) paralogs has aided the study of mammalian HSP90 (153, 154).  
A BLAST search probing for possible gp96 homologs identified the Drosophila 
molecule gp93, which proved interesting for multiple reasons. First, the two molecules 
were highly conserved despite the large evolutional gap, suggesting conserved function. 
Second, while gp96 chaperones TLRs, the original Toll is present in Drosophila (3, 4, 
51). Additionally, while mammals have alpha and beta integrins, Drosophila only has 
five alpha and two beta integrins. Furthermore, the gp96 cochaperone CNPY3 is part of a 
four member family in mammals, while Drosophila only has two CNPY family members 
(5, 46). Therefore, it is plausible that gp93 chaperones Toll and the Drosophila integrins 
with a CNPY cochaperone, similar to gp96 in mammals. Due to decreased Tolls, 
integrins, and CNPYs in Drosophila, this system will prove to be easier to study than the 
mammalian system, yet increase our knowledge of gp96 and aid development of 
therapeutics. The data demonstrating gp93 as an ortholog of gp96 has already been 
published in the Journal of Immunology (155). The remaining data is being prepared for 
publication.  
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Results:  
Identification of gp93  
The mammalian gp96 sequence was searched in the NCBI database in order to uncover 
genes with high sequence homology. Gp93 (NP_651601), a protein with unknown 
function in Drosophila melanogaster, was identified with a high degree of sequence 
conservation. The fly database was searched for this gene, confirming its identity and 
lack of known function. Sequence alignment demonstrated 74% homology at the amino 
acid level among Drosophila gp93, and both mouse and canine gp96 (Figure 1A). A 
breakdown of domain structure identified further similarities. Gp93 also contains an N-
terminal signal peptide (SP) for ER targeting which is 19% homologous. After the SP is 
an ATPase domain with 65% homology, suggesting the importance of ATP hydrolysis in 
conserved function. A charged middle domain is next with 48% homology, and a C-
terminal dimerization domain, important for function, is 61% homologous (3). Finally, 
the terminal amino acids of gp96 are KDEL, while those in gp93 are HDEL, both known 
ER retention signals (156). Even important residues for ATP binding and hydrolysis and 
thus chaperone function in gp96 are conserved in gp93: Glu103, Asn149, and Arg448 
(Figure 1A, highlighted yellow) (3, 13). Thus, both the amino acid sequence and domain 
structure are conserved between gp96 and gp93.  
 The crystal structure of canine gp96 has been solved in complex with a 
nonhydrolyzable ATP, 5’-adenylyl-β,γ-imidodiphosphate, demonstrating a twisted V 
structure of the gp96 dimer (13). It is possible to use this structure to map the sequence 
conservation among canine gp96, murine gp96, and Drosophila gp93. Depicted in Figure 
1B is the front and back (180°) of one monomer of gp96, with conserved residues in red. 
 67 
 
This figure illustrates areas within the structure which are highly preserved with invariant 
residues. For instance, the ATP binding pocket near the N-terminus appears to be highly 
conserved (Figure 1B, black arrows). Collectively, these data demonstrate that gp96 and 
gp93 are highly homologous, with shared amino acid sequences, important residues, and 
shared domain structure. Therefore, we decided to determine whether or not gp93 also 
shares chaperone function with gp96.  
 
Gp93 rescues gp96 client expression  
Since it is unknown whether gp93 functions as a chaperone, any possible client proteins 
are also unknown. Therefore, we decided to determine whether or not gp93 can function 
as a chaperone in a murine system and fold gp96 clients due to its high homology. For 
these studies, we utilized a murine gp96-mutant pre-B cell line, E4.126 (KO), which 
lacks functional gp96 (3). Therefore, these cells do not express surface α4, αL, β2, TLR2, 
or TLR4, but their expression can be rescued with gp96 restoration (3, 4, 20). We 
therefore tested whether gp93 can functionally replace gp96 and rescue the 
aforementioned gp96 clients. We utilized retroviral vectors expressing a GFP reporter in 
a bicistronic fashion and cloned both WT gp96 and gp93 into these vectors. We further 
cloned both molecules with Flag epitopes inserted just upstream of the ER retention 
signals for easier detection (No antibodies exist for gp93, and gp96 antibodies do not 
cross react with gp93: data not shown). The cloned vectors were transfected into Phoenix 
Eco cells for viral production, at which point viral particles were transduced into E4.126 
cells. GFP expression (Figure 2A), as well as Flag expression (Figure 2B) by both 
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intracellular stain and western blot, demonstrated high level transduction of each 
construct.  
 As a control, empty-vector (EV) transduced E4.126 cells failed to express the 
integrins α4, αL, or β2, nor TLR2 due to lack of gp96 expression (Figure 2C). As 
expected, both WT gp96 and gp96
Flag
 rescued all clients. Importantly, both WT and Flag 
tagged gp93 were also able to rescue all gp96 clients. While the MFI for all clients was 
about 5 in EV cells, the MFI for α4, αL, β2, and TLR2 increased to 313, 19.3, 7.96, and 
17.1 (respectively) in gp93
Flag
 cells. Integrin β1 however, a non-gp96 client protein, 
retained similar expression levels throughout the different cell types. Additionally, the 
Flag tag of either gp96 or gp93 did not impede chaperone function. Curiously, although 
gp93 was competent at chaperoning gp96 clients, it did so less efficiently. Comparing 
Flag expression levels, gp93
Flag
 is expressed higher than gp96
Flag
 (Figure 2B), yet the 
MFI of client proteins in gp93
Flag
 cells is lower than those in gp96
Flag
 cells (Figure 2C). 
Therefore, the chaperone function of folding both integrins and TLRs is conserved 
between gp96 and gp93. Moreover, the fact that gp93 is less efficient at folding than 
gp96 provides us a method by which to study structural elements necessary for chaperone 
function by comparing gp96 to gp93.  
 
Gp93 interacts with TLR9  
Besides cell surface TLRs, we decided to check if gp93 could also chaperone intracellular 
TLRs by determining whether or not gp93 could physically interact with TLR9. To this 
end, we further transduced gp96
Flag
 and gp93
Flag
 cells with TLR9
HA
, tagged at the C-
terminus. TLR9 expression was verified by intracellular stain and western blot, 
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demonstrating similar levels in each cell type (Figure 3A). We then performed 
immunoprecipitation experiments by pulling down Flag and immunoblotting for HA. 
Using the thiocleavable and membrane-permeable cross-linker DSP to stabilize the 
complex, we show that both gp96 and gp93 are able to interact with TLR9 (Figure 3B). 
Performing a reverse immunoprecipitation with HA pull down further verified these 
results (Figure 3C). Therefore, gp93 is thus able to chaperone multiple gp96 clients, 
located at both the cell surface and intracellularly.  
 
Gp96 and gp93 heterodimerize  
Since Drosophila gp93 is able to fold murine gp96 client proteins and it is highly 
homologous, we questioned whether or not gp96 and gp93 could heterodimerize. The C-
terminal canine gp96 oligomerization domain has been characterized, and the 
corresponding murine amino acids are 697-740 (18). This region is 55% conserved in 
gp93 (Figure 4A). For these experiments we utilized 14.GFP WT pre-B cells which 
express endogenous gp96. We further retrovirally transduced these cells with either 
gp96
Flag
 or gp93
Flag
. GFP reporter expression, as well as Flag and gp96 were determined 
by FACS (Figure 4B). Endogenous gp96 expression, as well as Flag transgene 
expression, was also verified by WB (Figure 4C). We then used these cells for gp96 IP 
with or without DSP crosslinker, followed by Flag WB. Interaction between gp96 and 
gp93 was only seen under crosslinking conditions (Figure 4D). More convincing was the 
reverse IP, where we pulled down Flag and looked at gp96 expression. We now saw 
weak gp96-gp93 interaction in the absence of crosslinker, and strong interaction in the 
presence of crosslinker (Figure 4E). Therefore, important residues within the 
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dimerization domain of gp96 and gp93 are highly conserved, allowing the two to 
dimerize.  
 
N-terminal disulfide bond formation in gp93  
Although gp93 can chaperone gp96 client proteins, it does so less efficiently. This 
allowed an opportunity to discover structural motifs important for function by examining 
differences between the two molecules which may account for the observed phenotype. 
Gp96 contains six cysteine residues (Cys
10
, Cys
11
, Cys
138
, Cys
576
, Cys
645
), which are 
important for disulfide bond formation. Ignoring the first two, which are located in the SP 
and cleaved upon entrance into the ER, we focused on the last three residues. The 
terminal two cysteines are conserved in gp93, but Cys
138
 is not (Figure 1A, asterisks). 
Our lab demonstrated that this residue is important for N-terminal dimerization in gp96 
(as opposed to C-terminal dimerization depicted in the crystal structure) (13, 155). We 
therefore sought to determine whether lack of this cysteine in gp93 would prevent N-
terminal dimerization, and thus make gp93 less efficient at folding client proteins.  
 The corresponding residue of gp96 Cys
138
 in gp93 is Ala
137
. In order to scrutinize 
this residue in gp93, we created the mutant gp93
A137C
 expressing the FLAG epitope. 
Upon retroviral transduction of E4.126 mutant pre-B cells, both the bicistronic GFP and 
Flag expression were detected indicating transgene expression (Figure 5A). Then we 
resolved gp96
Flag
, gp93
Flag
, and gp93
A137C
 under both reducing and nonreducing SDS-
PAGE (Figure 5B). While gp96 exhibited a dimer at 200kDa under nonreducing 
conditions, WT gp93 did not. However, gp93
A137C
 gained the ability to form a disulfide 
bonded dimer. So as seen in gp96, this N-terminal cysteine residue is important for 
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disulfide bond dependent dimerization. While gp93 lacks the ability to dimerize at the N-
terminus due to the presence of an alanine at this position, this ability can be restored by 
mutating the alanine to a cysteine.  
Since gp93
A137C
 gains N-terminal dimerization similar to gp96, we next explored 
whether or not this would improve chaperone efficiency. We therefore probed these cells 
for gp96 client expression. Surprisingly, gp93
A137C
 did not have increased α4, αL, β2, or 
TLR2 expression (Figure 5C). Client expression levels were similar between WT gp93 
and gp93
A137C
. Analogous to these results, gp96
C138A
 does not have decreased client 
expression, although this mutant does lose the ability to form N-terminal disulfide bond 
dependent dimerization (155). Therefore, although gp93
A137C
 gains the ability to form N-
terminal dimerization, this cysteine residue is not important for chaperone function.  
 
Exploring the client binding domain of gp93  
Resolution of the crystal structure of gp96 identified a C-terminal hydrophobic loop 
which protruded outward from the structure (13). Our lab recently identified this region 
(652-678) as the client binding domain (CBD) of gp96 for both integrins and TLRs (19). 
This region is highly conserved among different species of gp96, and is 63% homologous 
to HSP90. Comparing this region in gp96 to the corresponding residues in gp93 (649-
675) revealed only 44% homology (Figure 6A). We postulated that this difference could 
account for the decreased chaperone efficiency of gp93. Taking a closer look revealed 
that the first third of the CBD (652-660 in gp96) was surprisingly 78% homologous 
between gp96 and gp93, while the remaining two thirds of the region was only 28% 
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homologous. We therefore decided to test a mutant gp93 construct containing the gp96 
CBD instead of the WT gp93 sequence (gp93
96CBD
).  
gp93
96CBD
 was given a Flag tag and retrovirally transduced into E4.126 cells. 
Transgene expression was verified by GFP reporter and Flag expression by both FACS 
and WB (Figure 6B and C). Cells were then tested for gp96 client expression by FACS. 
Surprisingly, gp93
96CBD
 did not have improved expression of α4, αL, β2, or TLR2 (Figure 
6D). Contrary, this mutant expressed similar levels of αL and β2 as gp93Flag cells, yet 
decreased α4 and TLR2. This suggested that other motifs were responsible for the 
decreased chaperone efficiency seen with gp93.  
Although gp93
96CBD
 did not have improved chaperone function, we decided to test 
whether or not residues 649-675 in gp93 constituted a CBD similar to gp96. Furthermore, 
we took into account the differences in homology between the first third and remaining 
two thirds of the region. We hypothesized that since the first third was so conserved, it 
was likely important for function. Likewise, we postulated that the last two thirds were 
not as important for function since they were not conserved evolutionarily, and this 
would explain why gp93
96CBD
 did not have increased chaperone efficiency. We first 
focused on the later region by deleting it from gp93 (gp93
658-75D
). If our hypothesis was 
correct, then we could further pin point the important residues within the CBD to the first 
third. Yet if our hypothesis was wrong, then we could assume that one of the only five 
conserved residues in the last two thirds was important for function.  
gp93
658-75D
 was given a Flag tag and again retrovirally transduced into E4.126 
pre-B cells. These cells expressed high levels of the GFP reporter by FACS (Figure 7A). 
Transgene expression was also verified by intracellular stain and WB for Flag expression 
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(Figure 7B). We then analyzed these cells for gp96 client expression via FACS. 
Surprisingly, we found that gp93
658-75D
 had decreased expression of α4, αL, β2, and 
TLR2 (Figure 7C). Therefore, this suggested that one of the five conserved residues 
within this region was important for function.  
Of the five amino acids conserved in the last two thirds of the CBD, there are two 
hydrophobic tyrosine residues. Tyrosines are important because phosphate and sulfate 
groups can be added to them, which usually modulate enzymatic activity of the protein. 
Since gp96 is known to be phosphorylated, we therefore decided to mutate these two 
amino acids to alanines, which are smaller hydrophobic residues (gp93
2YA
). Similar to 
our previous constructs, we again added a Flag tag to this mutant and retrovirally 
transduced it into E4.126 pre-B cells. GFP reporter expression was first verified by FACS 
(Figure 8A). Transgene expression was then further verified by Flag intracellular stain 
and WB (Figure 8B). We then proceeded to analyze gp96 client expression levels by 
FACS. The gp93
2YA
 mutant had decreased expression of α4, αL, β2, and TLR2 (Figure 
8C). This proved that at least one of these tyrosines is important for function, and further 
implicated the role of phosphorylation or sulfation in gp96 chaperone function.  
 
Analyzing Drosophila CNPYs as possible gp93 cochaperones  
As discovered recently, CNPY3 is a gp96 cochaperone which promotes TLR folding (5). 
Since cochaperones are important aspects in chaperone biology, we probed whether or 
not gp93 also had an endogenous cochaperone. While mammals have four CNPY family 
members, Hirate showed that Drosophila possessed two CNPY members, CNPYa and 
CNPYb (46). Although CNPYb seemed most similar to CNPY3 as being the only family 
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members with highly basic domains, we decided to test both Drosophila CNPYs for the 
capacity to act as a cochaperone.  
 Utilizing the gp93
Flag
 pre-B cell line, we further transduced these cells with either 
CNPYa or CNPYb, both tagged with the Myc epitope at the C-terminus. E4.126 KO cells 
were also transduced with both constructs without gp93 as a control. GFP reporter 
expression showed high expression of both CNPYa and CNPYb in E4.126 cells (Figure 
9A). GFP expression was also increased in cells already containing gp93
Flag
. Western blot 
analysis of these cells for Myc further verified expression of both CNPY constructs in all 
cells (Figure 9B). We next analyzed CNPY cells by FACS for client expression. Neither 
CNPYa nor CNPYb alone expressed α4, αL, TLR2, or TLR4 (Figure 9C). Interestingly, 
these cells did express β2 at higher levels than gp93Flag cells, and this expression 
increased slightly with gp93 expression. However, cells containing gp93 together with 
either CNPY had decreased α4 and αL expression compared to gp93Flag cells. This 
suggests that both CNPYs may act as a direct chaperone for beta integrins, but not alpha 
integrins. As expected, however, gp93
Flag
 CNPYb cells had increased TLR2 and TLR4 
expression.  This suggests that CNPYb acts as a TLR cochaperone. gp93
Flag
 CNPYa cells 
had decreased TLR expression. Therefore, while both CNPYa and CNPYb seem to aid 
the expression of β2 integrin, only CNPYb aids TLR expression.  
 If CNPYb is indeed a cochaperone for gp93, then the two molecules should 
physically interact. Furthermore, since gp96 and gp93 are so homologous, we further 
wondered if gp96 could interact with CNPYb. We therefore further transduced CNPYb 
into gp96
Flag
 cells and verified transgene expression by Myc WB (Figure 10A). We then 
did an IP for Flag under crosslinking conditions followed by Myc WB. As expected, 
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gp93 does interact with CNPYb. Furthermore, gp96 was also able to interact with 
CNPYb (Figure 10B). We thus pondered whether gp93 could also interact with murine 
CNPY3. We again used gp96
Flag
 and gp93
Flag
 cells and transduced them with CNPY3 
containing the Myc epitope. Transgene expression was first verified by Myc WB (Figure 
10A). We then used all four cell lines to perform a Myc IP under crosslinking conditions, 
followed by Flag WB. As stated in the literature, gp96 and CNPY3 interacted (5). gp93 
was also able to interact with CNPY3. Furthermore, we again verified that both gp96 and 
gp93 could interact with CNPYb (Figure 10C). Thus, both gp93 and gp96 can interact 
with both CNPYb and CNPY3. This further verifies our hypothesis that CNPYb is a 
cochaperone for gp93, and demonstrates the highly conserved nature of the system.  
 
Cysteine residues important for CNPYb function  
Since CNPYb appears to be a TLR-specific cochaperone for gp93 much like CNPY3 is 
for gp96, we decided to investigate CNPYb further. Similar to Saposin, the CNPY family 
members each have six cysteine residues and are postulated to form shell like dimers 
(Figure 11A) (46). Besides intermolecular disulfide bonds, CNPYs are also postulated to 
form intramolecular bonds where the first cysteine binds the last as the protein folds upon 
itself as depicted in Figure 11B (UniProt CNPY3 Q9DAU1). Although CNPY3 and 
CNPYb are only 49% homologous at the amino acid level, all six cysteines are 
conserved, suggesting their importance in function (Figure 11C, yellow). We therefore 
decided to test the roles of these cysteines.  
 Since the six cysteine residues are postulated to bind each other, we only need to 
test the first three (Figure 11B). We therefore separately mutated C36, C39, and C92 to 
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alanines: CNPYb
C36A
, CNPYb
C39A
, and CNPYb
C92A
. These constructs were tagged with 
the Myc epitope and retrovirally transduced into E4.126 pre-B cells expressing gp93
Flag
. 
FACS showed that GFP expression increased over the parent gp93
Flag
 cells (Figure 12A). 
Transgene expression was then further verified by Myc WB (Figure 10B). Interestingly, a 
second band of approximately double the size (26 vs 52kDa) was also seen, indicating 
that CNPYb can indeed form dimers, although this band was curiously absent in CNPY3 
cells (Figure 10A). We then analyzed these cells for TLR levels by FACS. All three 
mutants had decreased TLR4 expression compared to gp93
Flag
 cells with WT CNPYb 
(Figure 12C). However, only gp93
Flag
 CNPYb
C39A
 cells had decreased TLR2 expression. 
C39 therefore appeared to be more important for chaperone function.  
 If CNPYb does indeed fold upon itself, then mutating the cysteine that binds to 
C39 should phenocopy it (Figure 11B). We therefore made the mutant CNPYb
C183A
 with 
a Myc epitope and retrovirally transduced it into gp93
Flag
 cells. GFP reporter expression 
was increased as compared to gp93
Flag
 cells as seen by FACS (Figure 13A). Transgene 
expression was further verified by Myc WB (Figure 13B). We then analyzed TLR 
expression by FACS. As hypothesized, gp93
Flag
 CNPYb
C183A
 cells phenocopied gp93
Flag
 
CNPYb
C39A
 cells with decreased TLR2 and TLR4 expression (Figure 13C). This 
suggested that C39 and C183 may indeed form a disulphide bond with each other, and 
that this bond is important for chaperone function. Furthermore, all CNPYb mutants 
except CNPYb
C92A
 displayed a dimeric band by Myc WB (Figure 12B and 13B). 
However, CNPYb
C92A
 was expressed at a much lower level than the other CNPYb 
mutants, and is therefore resolved more easily. We thus cannot rule out the possibility 
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that CNPYb
C92A
 does form dimers. So although breaking apart one disulfide bond affects 
chaperone function, it does not affect the ability to dimerize.  
 
Does gp93 chaperone Drosophila Toll?  
The endogenous clients of gp93 in Drosophila are unknown. Since gp93 is capable of 
chaperoning murine TLR2 and TLR4 and interacting with TLR9, it is possible that gp93 
chaperones Drosophila Toll. To test this, the Drosophila cell line S2* was utilized. RNAi 
was used to knockdown gp93, as well as CNPYa, CNPYb, and Toll as a control. Two 
different RNAi constructs were used to knockdown gp93, one which recognized the N 
terminus (gp93N), and one which recognized the middle (gp93M). An RNAi construct 
specific for the MigR1 vector, which does not recognize any Drosophila gene, was used 
as a negative RNAi control. Analysis by qRT-PCR reveals effective knockdown of each 
molecule (Figure 14A).  
 Since Toll antibodies are lacking, Toll protein expression could not be assayed 
directly. Therefore, Toll signaling was used to determine the presence or absence of Toll 
protein. RNAi treated cells were stimulated with recombinant SPZ (rSPZ), the 
endogenous ligand for Toll. The induction of downstream antimicrobial peptides, such as 
Drosomycin, was determined by qRT-PCR. Drosomycin induction could be seen in 
MigR1-RNAi cells treated with rSPZ compared to cells without rSPZ treatment. Cells 
with Toll-RNAi lacked Drosomycin induction, indicating that Toll knockdown was 
functionally efficient. However, cells with gp93, CNPYa, and CNPYb RNAi still had 
induction of Drosomycin (Figure 14B). Therefore, gp93 may not chaperone Toll, and 
neither CNPYa nor CNPYb may be involved in Toll folding as well. However, although 
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efficient mRNA knockdown of gp93, CNPYa, and CNPYb was seen, the protein 
expression levels were not known. It is possible that these molecules have long half-lives, 
and that the protein is not yet knocked down. Therefore, further examination of 
endogenous gp93 clients must be performed.  
 
Discussion:  
Our data unequivocally proves that Drosophila gp93 is a conserved ortholog of 
mammalian gp96, containing a large degree of sequence and structural homology. When 
expressed in a mammalian system effectively knocked out for gp96, gp93 is able to 
rescue gp96 client expression and can even physically interact with TLR9. Further 
demonstrating high homology between gp96 and gp93, the two molecules were capable 
of dimerizing. Mutational analysis of gp93 proved exceptionally useful. While gp93
A137C
 
gained the ability to dimerize at the C-terminus similar to gp96, chaperone function was 
not enhanced. With this knowledge, reciprocal studies were carried out in gp96, where 
gp96
C138A
 lost C-terminal dimerization, while chaperone abilities were unaltered (155).  
 Although the crystal structure of gp93 only depicts N-terminal dimerization, other 
data, such as the gp96
C138A
 mutant, demonstrate that C-terminal dimerization also occurs 
(13, 155). This seems probable, given the fact that HSP90, the cytosolic paralog of gp96, 
can dimerize at both termini. The presence of either ADP or a nonhydrolyzable ATP did 
not significantly alter gp93 structure (13). It is possible that either client or cochaperone 
binding may induce C-terminal dimerization. Gp96 remains in an open V shape, allowing 
either client and/or cochaperone to bind. Once bound, biochemical changes occur that 
cause C-terminal dimerization which may be necessary for client folding. Upon folding 
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of substrate, another biochemical change occurs which disrupts C-terminal dimerization 
and thus releases the client.  
 In order to further dissect the potential CBD of gp96 postulated from the crystal 
structure, the CBD of gp93 was swapped for that of gp96 (13). This mutant, however, did 
not have improved chaperone abilities. α4 and TLR2 expression were actually decreased. 
This may be due to unforeseen structural changes induced by the substitution of 27 amino 
acids. Furthermore, although the second half of the CBD is less conserved across species, 
the gp93
658-75D
 mutant had decreased client expression, implicating the importance of 
both halves of the CBD. Additionally, the terminal two tyrosines in the CBD were also 
important for function, as evidenced by the gp93
2YA
 mutant with decreased client 
expression. Although gp96 is known to be phosphorylated on serine and threonine 
residues, this data implicates a possible role for tyrosine phosphorylation in gp96/93 
function (10). Furthermore, this investigation aided the identification of the gp96 CBD 
(19).  
 In an attempt to characterize the role of either Drosophila CNPY in gp93 activity, 
CNPYb was determined to be a TLR specific cochaperone similar to CNPY3 with gp96 
(5). Surprisingly, both CNPYa and CNPYb rescued β2 expression in cells lacking gp93, 
and to a level higher than that in gp93 cells. The addition of gp93 to either CNPY only 
mildly increased its expression. Therefore, both CNPYs appear to play a dominant role in 
promoting β2 expression. Furthermore, gp93 cells with CNPYa had decreased levels of 
TLRs, and both CNPYs had decreased alpha integrin expression compared to gp93 cells. 
Therefore, the possibility remains that these CNPYs may negatively regulate certain gp93 
clients while promoting others, perhaps by inhibiting ATPase activity. This is plausible, 
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as various cochaperones of HSP90 have been found to either activate or inhibit ATP 
hydrolysis, thereby affecting chaperone function (153).  
 A deeper investigation of CNPYb demonstrated that this molecule is able to 
physically interact with gp93, which is a characteristic of a cochaperone. Additionally, 
gp96 was also able to interact with CNPYb, while gp93 was also able to interact with 
CNPY3, identifying further similarities between the mammalian and Drosophila systems. 
Since not much is known about mammalian CNPY3, we decided to investigate CNPYb 
further in order to learn more about this molecule using a simpler system. Analyzing the 
six characteristic saposin-like cysteines by mutational analysis demonstrated that 
although C36 and C92 were important for TLR4 expression, only C39 and C183 were 
required for both TLR2 and TLR4 expression. It is possible, therefore, that C39 and C183 
form a disulfide bridge important for general cochaperone function. However, CNPYb 
seems to differentially interact with different TLRs. This is likely, given that such 
differences have been seen with CNPY3 (49).  
 The elucidation of the endogenous gp93 clients will enable better utilization of the 
Drosophila system for understanding gp96 biochemistry. Unfortunately, preliminary data 
suggests that gp93 does not chaperone Toll. However, although gp93 mRNA levels were 
efficiently knocked down, the protein level is unknown. If gp93 has a long half-life 
similar to gp96, then it is possible that we did not achieve knockdown of gp93 protein. 
Therefore, further studies must be performed in order to conclude whether or not gp93 
chaperones Toll. Furthermore, it is possible that gp93 chaperones the other Toll-related 
proteins (Toll-2 to Toll-9). However, being that TLR4 was discovered due to its 
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homology to Toll, and that gp93 was able to rescue TLR4 expression, we remain firm on 
our hypothesis that gp93 chaperones Toll.  
 After publication of our work identifying gp93 as the Drosophila ortholog of 
gp96, another group published a paper characterizing gp93 (155, 157). Maynard and 
colleagues demonstrated that gp93 KO flies harbor a growth defect, and die at the third 
instar larval stage, never developing into adult flies. Closer examination demonstrated 
multiple defects in the larval midgut. KO larva had decreased nutrient uptake, reduced 
gut motility, abnormal septate junction structure, decreased gut acidification, abnormal 
copper cell structure, reduced insulin signaling, and atypical amino acid and triglyceride 
mobilization. KO flies thus display a starvation-like metabolic disease (157). In 
Drosophila, integrins αPS1, αPS3, βPS, and βν are all expressed in the midgut (56, 57, 60, 
62). In βPS KO flies, there is a defect in migration of the primordial midgut cells. 
Furthermore, when both βPS and βν are absent, the phenotype is exacerbated, and the 
migration of these cells is blocked completely (57). Therefore, gp93 KO flies seem to 
phenocopy βPS/βν double KO flies. Since gp96 chaperones select integrins, this data 
highly suggests that gp93 can chaperone Drosophila integrins.  
 In conclusion, gp93 is the Drosophila ortholog of mammalian gp96, being able to 
chaperone both integrins and TLRs. A137 of gp93 fails to support C-terminal 
dimerization, yet the ability to dimerize at the C terminus did not affect chaperone 
function. Residues 658-75 of the CBD, and tyrosines 74-75 in particular were important 
for chaperone function, further implicating the role of phosphorylation in gp93 
regulation. CNPYb is a TLR specific cochaperone for gp93, while CNPYa and CNPYb 
are possible negative regulators of α4 and αL. Furthermore, these CNPYs are a dominant 
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requirement for β2 integrin (Figure 15). So not only do these CNPYs differentially 
modulate TLRs versus integrins, but there appears to also be differences in alpha versus 
beta integrin regulation. Not only does the study of the Drosophila gp93 system create an 
avenue to better study the gp96 system, but insights gained from gp93 have already aided 
the discovery of certain aspects of gp96 biochemistry, with hopes of uncovering more.  
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Figure 1: Sequence alignment and structure conservation between mammalian gp96 
and Drosophila gp93. (A) Amino acid sequence alignment among murine (m) gp96, 
canine (c) gp96, and Drosophila (d) gp93. Conserved residues among all three are 
highlighted red. Residues conserved between two are blue. Similar amino acids are 
highlighted green. Weakly similar residues are grey. Yellow highlighted residues are 
those important for ATPase activity. Numbers denote amino acid position. Asterisks 
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indicate cysteine residues. (B) Conservation mapping using the canine gp96 structure. 
Conserved residues in ‘A’ are highlighted in red. Nonconserved residues are grey. The 
front and back (180° turn) of one monomer of gp96 is depicted. The N-terminus is at the 
top, and the C-terminus is at the bottom. Black arrows indicate the ATP binding pocket.  
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Figure 2: gp93 expressed in murine gp96-mutant pre-B cells can rescue gp96 client 
expression. E4.126 murine pre-B cells, deficient for gp96, were retrovirally transduced 
 86 
 
with the indicated constructs and then analyzed. (A) GFP reporter expression of the 
indicated cells was determined by FACS. (B) Flag intracellular stain of gp96
Flag
 and 
gp93
Flag
 cells (top). Flag western blot of the indicated cells (bottom). β-actin was used as 
a loading control. (C) FACS staining of gp96 clients (α4, αL, β2, and TLR2) as well as 
one non-client protein (β1). Shaded histograms indicate isotype staining. Numbers denote 
MFI. Data shown is one of many experiments with similar results.  
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Figure 3: Both gp96 and gp93 interact with TLR9. E4.126 pre-B cells already 
transduced with either gp96
Flag
 or gp93
Flag
 were then further transduced with TLR9
HA
 and 
then analyzed. (A) HA intracellular stain of the indicated cells (left). Shaded histogram 
indicates isotype control stain. Numbers denote MFI. HA western blot with β-actin 
loading control (right). (B) Flag (F) IP of gp96
Flag
 and gp93
Flag
 cells with TLR9
HA
 
followed by WB for HA and Flag. Isotype control antibody was used (iso). Cells were 
treated with (+) or without (-) DSP crosslinker. (C) Same as in ‘B’, but IP for HA (H) or 
the appropriate isotype control antibody. Data are representative of two separate 
experiments.  
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Figure 4: gp96 and gp93 heterodimerize. (A) Amino acid sequence alignment of the 
dimerization domain between murine (m) gp96 and Drosophila (d) gp93. Conserved 
amino acids are highlighted red, and similar residues are highlighted blue. Numbers 
denote amino acid position. (B) 14.GFP (WT) murine pre-B cells were retrovirally 
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transduced with either gp96
Flag
 or gp93
Flag
 and then analyzed for GFP reporter, Flag, and 
gp96 expression by intracellular stain. Shaded histograms denote isotype controls. (C) 
gp96, Flag, and β-actin WB of the indicated cells. (D) Gp96 (96) IP with (+) or without   
(-) DSP crosslinker, followed by Flag and gp96 WB. (E) Reverse IP of Flag (F) with or 
without DSP, followed by gp96 WB. Isotype (Iso) control antibody was used. Data 
represent one of two experiments with similar results.  
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Figure 5: gp93
A137C
 rescues N-terminal disulfide bond dimerization, yet does not 
enhance chaperone function. E4.126 murine pre-B cells were transduced with the 
indicated constructs and then analyzed. (A) GFP reporter expression of gp93
A137C
 cells by 
FACS (left). Flag intracellular stain (right). (B) gp96
Flag
, gp93
Flag
, and gp93
A137C
 cells 
were resolved by SDS-PAGE with (+DTT) or without (-DTT) denaturing conditions. The 
membranes were blotted with Flag and β-actin loading control antibodies. Numbers 
denote molecule size in kDa. (C) FACS for gp96 client proteins (α4, αL, β2, and TLR2). 
Shaded histogram denotes isotype control stain. Data represent one of two experiments 
with similar results.   
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Figure 6: gp93
96CBD
 does not have improved client expression. (A) Amino acid 
sequence alignment of the CBD among HSP90, gp93, and different species of gp96. 
Conserved residues are highlighted red. Amino acids conserved among the majority are 
highlighted blue, while those conserved by a minority are highlighted green. Residues in 
green font are similar amino acids. Numbers denote amino acid length of the CBD. (B) 
E4.126 murine pre-B cells were transduced with gp93
96CBD
 and then analyzed by FACS 
for GFP reporter expression. (C) Flag intracellular stain of gp93
96CBD
 cells (left). Flag 
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WB of the indicated cells with β-actin loading control (right). (D) FACS of gp96 client 
proteins (α4, αL, β2, and TLR2). Shaded histogram denotes isotype control stain. Data 
represent one of two experiments with similar results.  
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Figure 7: gp93
658-75D
 has decreased client expression. E4.126 murine pre-B cells were 
retrovirally transduced with the indicated constructs and then analyzed. (A) GFP reporter 
expression of gp93
658-75D
 cells by FACS. (B) Flag intracellular stain of gp93
658-75D
 cells 
(left). Flag WB of the indicated cells with β-actin loading control (right). (C) FACS of 
gp96 client proteins (α4, αL, β2, and TLR2). Shaded histogram denotes isotype control 
stain. Data represent one of two experiments with similar results.  
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Figure 8: gp93
2YA
 has decreased client expression. E4.126 murine pre-B cells were 
transduced with the indicated constructs and then analyzed. (A) GFP reporter expression 
of gp93
2YA
 cells by FACS. (B) Flag intracellular stain of gp93
2YA
 cells (left). Flag WB 
with β-actin loading control of the indicated cells (right). (C) FACS of gp96 client 
proteins (α4, αL, β2, and TLR2). Shaded histogram denotes isotype control stain. Data 
represent one of two experiments with similar results.  
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Figure 9: CNPYa and CNPYb improve β2 expression while only CNPYb improves 
TLR expression. E4.126 murine pre-B cells retrovirally transduced with the indicated 
constructs were then analyzed. (A) GFP reporter expression of the indicated cells by 
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FACS. (B) WB for Flag (gp93), myc (CNPYa and CNPYb), and β-actin loading control. 
(C) FACS of the indicated cells for gp96 client proteins (α4, αL, β2, TLR2, and TLR4). 
Shaded histogram denotes isotype control stain. Numbers indicate MFI. Data represent 
one of two experiments with similar results.  
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Figure 10: Gp96 and gp93 both interact with CNPY3 and CNPYb. E4.126 murine 
pre-B cells already transduced with either gp96
Flag
 or gp93
Flag
 were further transduced 
with either CNPY3 or CNPYb and then analyzed. (A) Myc WB of the indicated cells. β-
actin was used as a loading control. (B) Flag (F) IP under DSP crosslinking conditions, 
followed by Myc WB. (C) Reverse IP of Myc (M) with DSP, followed by Flag WB. 
Isotype (Iso) control antibody was used. Data represent one of two experiments with 
similar results.  
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Figure 11: Drosophila CNPY structure and sequence alignment. (A) Schematic of 
Drosophila CNPYa and CNPYb. Signal peptide, SP, green. Cysteine residues, C, yellow. 
Basic region, BR, grey. ER retention signal, ER, purple. (B) Model of CNPYb folded 
clam structure. Lines represent disulfide bonds between Cysteine/C residues. Colors are 
as in ‘A’. (C) Amino acid sequence alignment between murine (m) CNPY3 and 
Drosophila (d) CNPYb. Conserved residues are highlighted red. Similar residues are 
blue. Cysteines are highlighted yellow. Numbers indicate amino acid position.  
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Figure 12: Cysteines 36, 39, and 92 of CNPYb are important for folding of TLRs. 
E4.126 murine pre-B cells already transduced with gp93
Flag
 were further transduced with 
the indicated CNPYb construct and then analyzed. (A) GFP reporter expression of the 
indicated cells by FACS. (B) Myc (all CNPYs) and β-actin control WB. Numbers denote 
molecule size in kDa. (C) FACS of the indicated cells for TLR2 and TLR4 expression. 
Shaded histograms denote isotype control stains. Data represent one of two experiments 
with similar results.  
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Figure 13: CNPYb
C183A
 phenocopies CNPYb
C39A
. E4.126 murine pre-B cells already 
transduced with gp93
Flag
 were further transduced with the indicated CNPYb construct and 
then analyzed. (A) FACS for GFP reporter expression of the indicated cells. (B) WB for 
Flag (gp93), Myc (all CNPYs), and β-actin loading control. Numbers denote molecule 
size in kDa. (C) FACS for TLR2 and TLR4 of the indicated cells. Shaded histograms are 
isotype control stains. Data represent one of two experiments with similar results.  
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Figure 14: gp93 may not chaperone endogenous Drosophila Toll. (A) Gp93, Toll, 
CNPYa, and CNPYb qRT-PCR of S2* cells treated with the indicated RNAi constructs 
for four days. The MigR1 RNAi construct was used as a negative control. (B) RNAi 
treated S2* cells were given 1µM 20-hydroxyecdysone for 24 hours on day six. On day 
seven, cells were treated with or without (+/-) 2.4nM rSPZ for 6 hours. Cells were then 
harvested and assayed for Drosomycin RNA levels by qRT-PCR. Rp49 was used as an 
internal control. Data represent one of two experiments with similar results.  
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Figure 15: Model of gp93, CNPYa, and CNPYb chaperone function. Our data 
indicates that CNPYb aids gp93 in chaperoning TLRs. Gp93 chaperones integrins α4, 
αL, and β2 independently of any CNPY. CNPYa and CNPYb are able to improve β2 
expression on their own.  
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Chapter 4 
 
Macrophage-Specific gp96 Promotes Colitis-Associated Colon Tumorigenesis 
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Rationale:  
Although both gp96 and macrophages have been implicated in promoting cancer, the 
majority of work done on macrophages has involved the cell’s deletion (66, 82). In order 
to further this area of research and design better therapeutics targeting macrophages in 
cancer, the mechanisms which activate protumor properties of macrophages need to be 
better delineated. PRRs are a large class of molecules which are able to activate 
macrophages. TLRs are a type of PRR which are chaperoned by gp96, and signal through 
MyD88 to induce NF-κB signaling. Since TLRs induce inflammation and inflammation 
has been shown to promote cancer, TLRs are an attractive molecule to study in the role of 
cancer. In particular, our interest was focused on colitis and colitis-associated colon 
cancer.  
 The literature revealed a protective role for NF-κB in general, and TLR2 and 
TLR4 specifically in colitis. However, this picture became more obscured in colon 
cancer, where NF-κB appeared to be both protective and promoting. This identifies 
conflicting roles for receptors upstream of NF-κB. MyD88 proved to be protective in 
colon cancer, and a look at upstream receptors demonstrated that IL1R had no effect, 
while IL18R was also protective. The direct role of TLRs, however, was not investigated. 
As well, other receptors upstream of NF-κB must be studied in order to determine which 
receptors are responsible for cancer promotion.  
 Since the TLR family is so large, a pan-TLR KO mouse is hard to develop. 
Although many investigations have used the downstream adaptor MyD88, deficiency of 
this gene also interferes with IL1R and IL18R. The knockdown of gp96, however, 
provides a pan-TLR KO mouse (except TLR3) without affecting IL1R or IL18R. We 
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therefore decided to use macrophage-selective gp96 KO mice as a means to study 
macrophage activation via TLRs in colitis-associated colon tumorigenesis.  
 
Results:  
KO mice are less susceptible to DSS colitis  
LysM Cre gp96
Flox/Flox
 (KO) mice were described previously. Yang demonstrated that 
there were different levels of gp96 knock down depending on the macrophage tissue of 
origin, with more mature macrophages having greater knock down (4). In order to study 
colitis-associated colon tumorigenesis, we decided to first analyze colitis. We treated WT 
and KO mice with 3% DSS for five days, and then euthanized the mice at either day five 
or day eight. DSS is a chemical irritant which breaks apart epithelial tight junctions, both 
destroying the architecture and allowing commensal bacteria to encounter lamina propria-
resident leukocytes. Histological examination of the colons by H&E staining 
demonstrated normal architecture basally in both WT and KO mice. Upon DSS exposure, 
WT mice had worse pathology than KO mice at both day 5 and day 8, characterized by 
greater erosion, loss of structure, and immune infiltrate (Figure 16A). When scored 
blindly by a pathologist, the worst pathology was seen with day 8 colons. Furthermore, 
WT mice had significantly worse pathology at day 8 than KO mice (Figure 16B).  
 Colonic shortening, a characteristic of colitis, was examined at time of sacrifice. 
At day 5 of DSS exposure, colonic shortening was seen in both WT and KO mice, but it 
was significantly more drastic in WT mice. At day 8, both mice started to recover, but no 
significant difference was seen (Figure 16C). During treatment, mice were also analyzed 
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daily for stool consistency. WT mice had significantly worse stool consistency scores 
than KO mice (Figure 16D).  
Commensal bacteria can trigger leukocytes via TLRs, and since gp96 chaperones 
TLRs, we decided to look at differences in TLR activation. We analyzed cytokine 
expression downstream of TLR activation by qRT-PCR of distal colon samples. The 
following cytokines were analyzed: IL-1β, IL-6, IL-17A, IL-17F, IL-12 p35, IL-12/23 
p40, IL-23 p19, IL-18, IL-22, IFNγ, and TNFα. A trend developed whereby WT mice 
expressed higher cytokine levels, although insignificant. The macrophage marker F4/80 
was also analyzed. Although its expression significantly increased on day 8 upon 
inflammation, similar levels were seen between WT and KO mice, suggesting similar 
macrophage recruitment (Figure 16E). Collectively, these data demonstrate that KO mice 
are less susceptible to DSS-induced colitis.  
 
KO mice are less susceptible to colitis-associated colon tumorigenesis  
Since KO mice were protected from colitis, we expected to see an exacerbated phenotype 
with colitis-associated colon tumorigenesis. Mice were administered with the carcinogen 
AOM via ip injection on day one. Mice were then treated with three cycles of DSS as 
described in the methods, and then sacrificed on week 20. Nearly 100% tumor incidence 
was seen in WT and KO mice (data not shown). Upon necroscopy, macroscopic tumors 
could be seen in both WT and KO mice when the colons were cleaned and opened 
longitudinally. Distal and medial localization of the tumors was similar between WT and 
KO mice, while the proximal colon was void of tumors (Figure 17A). Closer pathological 
examination of tumors via H&E staining revealed differences between WT and KO mice. 
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WT mice had higher grade adenomas with greater immune infiltration than KO mice 
(Figure 17B). When scored blindly by a pathologist, WT mice indeed had higher scores 
(Figure 17C). When adenomas were enumerated, WT mice had significantly more tumors 
than KO mice (Figure 17D). Upon closer scrutiny, WT mice had significantly more large 
tumors than KO mice, being more than 2mm in diameter (Figure 17E). When scored, WT 
mice also had worse tumor burden than KO mice (Figure 17F). Therefore, KO mice seem 
to be more resistant to the AOM+DSS treatment.  
Similar to our colitis experiments, we again sought to determine differences in 
cytokine levels by qRT-PCR of distal colon samples. As in Figure 16E, we analyzed the 
same cytokines and again found the trend whereby WT mice exhibited greater expression 
levels (Figure 18). Importantly, IL-17A, IL-17F, TNFα, and IL-23 (but not IL-12) were 
significantly decreased in KO mice. This data is consistent with the literature which 
shows a role for IL-17 and IL-23 in tumor promotion (113-115, 117, 120).  
 
Similar macrophage markers in WT and KO mice  
Since gp96 is only knocked out of macrophages, it is important to investigate different 
macrophage populations within our mice. We therefore decided to look at different 
macrophage markers in distal colon samples from our mice by qRT-PCR. The general 
macrophage markers CD11b and F4/80 were similar between WT and KO mice in both 
untreated and AOM+DSS treated samples. Both M1 (iNOS) and M2 (ARG1, Cox2, and 
IDO1) markers were also similar between WT and KO mice (Figure 19A). We also 
looked at F4/80 expression by immunohistochemistry, which demonstrated similar 
localization and number of macrophages in both WT and KO untreated colons and 
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AOM+DSS-induced tumors (Figure 19B). Therefore, differences seen between WT and 
KO mice are not due to differences in macrophage recruitment, but rather to differences 
in macrophage activation.  
 
Less CD4
+
 IFNγ+ cells in KO mice  
We next sought to uncover differences in immune activation by looking at different T cell 
subsets. Importantly, no differences were seen in overall CD4
+
 or CD8
+
 lamina propria T 
cells from either untreated or AOM+DSS treated WT and KO mice when analyzed by 
FACS (Figure 20A and C). The CD4 to CD8 ratio was also unaltered between genotypes 
(Figure 20D). However, when stimulated ex vivo, we did see a significant decrease in 
CD4
+
 IFNγ+ cells in AOM+DSS treated KO mice (Figure 20B and E), but not in other T 
cell subsets (data not shown). Therefore, KO mice exhibit less CD4
+
 IFNγ+ cells, such as 
Th1 cells, contributing to a decreased immune response compared to WT mice.  
 
KO mice are protected from Wnt activation and β-catenin mutation  
We next decided to look into the Wnt pathway, as its activation has been associated with 
various cancers (124). We first performed qRT-PCR on distal colon samples for various 
Wnt pathway molecules and downstream targets: Axin, β-catenin, cMyc, CyclinD1, 
Fzd1, and p53. As expected, all molecules were significantly increased upon AOM+DSS 
exposure. Furthermore, a trend again emerged whereby WT mice harbored greater 
expression levels than KO mice. Notably, only the Wnt receptor Fzd1 and the 
downstream target p53 were significantly greater in WT mice than in KO mice (Figure 
21A).  
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 Mutations within exon 3 of β-catenin occur under the AOM+DSS model, as 
previously reported (100). Exon 3 in particular is important for protein regulation, 
harboring GSK3β phosphorylation sites. We therefore sequenced β-catenin in our colon 
samples. Neither WT nor KO untreated mice had any mutations. As expected, more than 
60% of AOM+DSS treated WT mice exhibited mutations within exon 3. Strikingly 
however, not a single KO mouse treated with AOM+DSS had any mutations (Figure 
21B). Upon closer scrutiny, individual WT mice had anywhere from zero to six 
mutations within exon 3 (Figure 21C). Mutations found in treated WT mice were not 
only located in exon 3, but were also clustered around the GSK3β phosphorylation sites 
(Figure 21D). Therefore, the β-catenin mutation rate in KO mice is drastically reduced.  
Since disruption of GSK3β phosphorylation sites can activate β-catenin, we next 
assayed β-catenin nuclear localization by immunohistochemistry. Both cytoplasmic and 
nuclear expression patterns were similar between WT and KO mice in areas of normal 
epithelium and within the tumor (Figure 21E). Collectively however, these data indicate 
that WT mice exhibit altered Wnt pathway activation and β-catenin mutation rates than 
KO mice.  
 
DNA repair is activated with inflammation-associated colon tumorigenesis  
Due to striking differences in β-catenin mutation rate between WT and KO mice, we 
wondered if DNA repair pathways would be altered. We focused on molecules involved 
in the MMR and BER pathways of DNA repair, as they have been implicated in colon 
cancer and repair of O
6
-methylguanine containing mismatches caused by AOM. We first 
checked DSS samples for expression of the MMR genes MLH1, MSH2, and MSH6, as 
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well as the BER gene AAG by qRT-PCR. No significant differences were seen (Figure 
22A). When we analyzed the same genes in AOM+DSS treated samples, we saw 
significant increases upon treatment. However, there were again no differences between 
WT and KO mice (Figure 22B). Therefore, the reason underling decreased β-catenin 
mutation rate in KO mice remains unknown.  
 
Bone marrow transplantation confirms the role of hematopoietic cells  
Utilizing LysM Cre-mediated gp96 deletion in our system allows a remote possibility that 
the recombinant Cre could be ectopically expressed in parenchymal cells as well as 
macrophages, thus complicating our interpretation of the results. To rule out this 
possibility, we performed bone marrow transplantation studies. Congenic WT mice were 
lethally irradiated, and then reconstituted with either WT (WT→WT) or KO (KO→WT) 
bone marrow. We first verified over 90% donor chimerism by FACS of peritoneal 
exudate cells, analyzing gp96 expression on gated F4/80 cells (Figure 23A). These mice 
were then subjected to the AOM+DSS regimen. We found that treated KO→WT mice 
gained more weight than WT→WT mice (Figure 23B). Similar to our previous data, 
KO→WT mice again exhibited decreased tumor burden compared to WT→WT mice 
(Figure 23C). F4/80 immunohistochemistry also showed similar macrophage localization 
and number between WT→WT and KO→WT mice (Figure 23D). These data 
collectively show that parenchymal cells are not affected, and that the phenotype of 
decreased susceptibility seen in KO mice is indeed hematopoietic intrinsic.  
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Discussion:  
The focus of our work was to determine the role of macrophage-specific gp96 in cancer. 
We used gp96 as a means to produce a pan-TLR knockout in order to investigate the role 
of macrophage activation. Up to now, the majority of studies on the role of macrophages 
in cancer have used macrophage depletion strategies to answer this question. However, 
we were interested in how macrophages mediated these effects, and in particular, which 
PRRs were responsible for activation of their tumor promoting roles. Since TLRs are 
integral in promoting inflammation, we decided to look at a model of inflammation-
induced colon tumorigenesis: AOM+DSS. In addition, DSS-colitis was checked 
separately in order to better characterize this model. 
Our data demonstrate colitis and colon cancer promoting roles of macrophage-
specific gp96. Upon DSS treatment, KO mice were protected from colitis with decreased 
pathology, colonic shortening, stool consistency, and inflammatory cytokine expression. 
This role was further amplified in colitis-associated colon tumorigenesis, where gp96 
again played a promoting role. KO mice displayed decreased pathology, tumor number, 
tumor size, and tumor burden. This was characterized with decreased inflammatory 
cytokine expression, particularly IL-17, IL-23, and TNFα. These three cytokines, which 
have previously been implicated in cancer, are therefore possible mediators of gp96 
cancer promoting functions. The use of bone marrow transplantation coupled to 
AOM+DSS treatment demonstrated the hematopoietic intrinsic role of the phenotype 
seen in KO mice, where KO→WT mice harbored decreased tumor burden compared to 
WT→WT mice.  
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 Scrutinizing macrophage subsets, no differences were found between WT and KO 
mice in either M1 or M2 markers. Likewise, macrophage infiltration into the tumor 
microenvironment was also comparable, demonstrating that integrin loss due to gp96 
absence did not affect macrophage migration. Upon AOM+DSS treatment, CD4
+
 IFNγ+ 
cells were decreased in KO mice, suggesting that macrophage specific gp96 may promote 
maintenance of Th1 cells in colon tumorigenesis. Wnt signaling also appeared to be down 
regulated in KO mice, yet there was no difference in nuclear β-catenin translocation 
within the tumor. Furthermore, mutations within the β-catenin gene characteristic of the 
AOM+DSS model were absent in KO mice.  
 In order to determine the apparent difference in mutation rates within these mice, 
DNA repair pathways were investigated. No differences were seen in colitis. With colon 
cancer, however, there was a marked increase of DNA repair genes with AOM+DSS 
treatment. However, there were no differences between WT and KO mice. It is possible 
that differences exist in other DNA repair genes not studied in this model. As well, there 
may be epigenetic differences affecting mutation rates independent of DNA repair. Most 
likely however, TLR signaling in WT mice leads to increased levels of reactive oxygen 
and nitrogen species (RONS) which can directly insult DNA. With more DNA insult in 
WT mice than KO mice, the DNA repair machinery is not able to keep up with correcting 
these changes, and mutations are thus able to persist and be passed down to progeny 
cells.   
 Macrophage-specific gp96 may exert its affects through TLRs to promote colitis. 
This is complimentary to the literature where NK-κB displays colitis promoting roles, yet 
the upstream receptors involved are not clearly delineated. However, a pan-TLR specific 
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KO mouse does not exist, and only a few TLR KO mice have been used for colitis 
experiments. Therefore, our data for the first time shows that the culminative effect of 
knocking out all TLRs (except TLR3) exhibits a colitis promoting role. However, the role 
of other NK-κB signaling receptors needs to be investigated in order to ascertain a 
comprehensive understanding of the role of NK-κB in colitis.  
 Although macrophages have pro-tumor properties, the activating mechanism is 
unknown. In inflammation induced cancers, especially within the intestines where 
commensals are prevalent, PRRs are likely to be the culprit. Macrophage-specific gp96 
KO creates macrophages which lack all TLRs except TLR3. The literature demonstrated 
that NK-κB harbors both tumor promoting and protective roles in the AOM+DSS model. 
However, the role of individual upstream receptors was unclear. Our data therefore 
demonstrates that the upstream TLR receptor family plays a promoting role. This is in 
contrast to IL18R which plays a protective role, also implicating the role of the 
inflammasomes. Furthermore, MyD88 also plays a protective role, demonstrating that the 
role of IL18R is dominant over that of TLRs. As well, TLR2 is protective while TLR4 
promotes colon cancer. Therefore, although specific TLRs may have different effects, the 
collective effect of all TLRs is tumor promoting.  
 Under homeostatic conditions within the colon, the epithelial cells create a 
physical barrier separating the intestinal lumen full of commensal bacteria from the 
lamina propria. Immune cells such as macrophages within the lamina propria produce IL-
10 to maintain an immunosuppressive environment (Figure 24A). In the case of DSS-
colitis, epithelial tight junctions are directly antagonized by DSS, creating space in 
between enterocytes by which commensal bacteria can pass into the lamina propria. 
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Bacterial-derived ligands then stimulate macrophages via cell surface TLRs to secrete 
proinflammatory cytokines. Macrophages promote inflammation which causes colitis 
(Figure 24B). When AOM is further added, IL-17, IL-23, and TNFα in particular are 
induced by macrophages. As a carcinogen, AOM can directly cause DNA mutations. As 
well, proinflammatory macrophages are known to secrete RONS which also cause 
mutations. Since KO mice are devoid of β-catenin mutations, we believe that this is the 
direct result of RONS, which we assume to be drastically reduced in KO mice if 
macrophages are not activated.  As well, the inflammatory environment induced the Wnt 
pathway within enterocytes. This, coupled with activating β-catenin mutations as well as 
the induction of other oncogenes, led to increased proliferation and adenoma formation 
(Figure 24C). Whether other genes harbor mutations, and if differences exist between 
WT and KO mice, is unknown.  
In conclusion, macrophage-specific gp96 promotes colitis and colitis-associated 
colon cancer. Therefore, TLR expression on macrophages may activate protumor 
properties of the cells, and TLRs are at least one receptor upstream of NF-κB which 
promotes colon cancer. This data pinpoints macrophage-derived gp96 and TLRs as 
therapeutic targets against colitis and colon cancer.  
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Figure 16: Macrophage-specific gp96 KO mice are less susceptible to colitis. WT and 
KO mice were treated with 3% DSS for 5 days, and then sacrificed on either day five 
(D5) or day eight (D8). Three experiments were performed with similar results. (A) H&E 
staining of transverse colon sections from untreated (UT) or DSS treated mice. (B) 
Pathology scores based on ‘A’. N=3 (C) Colon length measured from cecum to anus at 
time of sacrifice. N=5 (D) Stool was scored daily for consistency as follows: 0, well-
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formed stool; 1, semi-formed stool; 2, semi-formed stool that adheres to the anus; 3, 
liquid stool/diarrhea. N=10 for days 0-5, n=5 for days 6-8. (E) qRT-PCR of distal colon 
samples for various cytokines. β-actin was used as an internal control, and data was 
analyzed using the dCT method. N=5 Error bars depict standard deviation in ‘B-D’, and 
standard error in ‘E’. p<0.05 *, p<0.005 **  
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Figure 17: Decreased tumor burden in Macrophage-specific gp96 KO mice. Mice 
were injected ip with 12.5mg/kg AOM on day 1, followed by two cycles of 2.5% DSS for 
5 days on weeks 2 and 5, and then one cycle of 2% DSS for 4 days on week 8. Mice were 
monitored weekly and then sacrificed on week 19-21. Two experiments were performed 
with similar results. (A) Gross photographs of colons ex vivo which were washed and 
opened longitudinally after AOM+DSS treatment. (B) H&E staining of colonic tumors. 
(C) Pathology score based on ‘B’. N=6 WT and 7 KO. (D) Colons were fixed in 
paraformaldehyde, and then stained with methylene blue for adenoma visualization. The 
number of tumors per mouse was counted using a dissecting microscope. (E) Distribution 
of tumors based on size. The diameter of each tumor was measured in two perpendicular 
directions, and then the average diameter was used for tumor size. (F) Tumor burden was 
calculated for each mouse as the number of tumors times the average tumor size. N=9 
WT and 16 KO for D-F. Error bars depict standard deviation.  p<0.05 *, p<0.005 **  
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Figure 18: KO mice harbor less cytokine expression. Upon sacrifice of mice treated 
with AOM+DSS (AOM), the distal colon was harvested for RNA. After reverse 
transcription into cDNA, qRT-PCR was performed for various cytokines. β-actin was 
used as an internal control, and data was analyzed using the dCT method. Error bars 
depict standard error. UT, untreated. N=7 WT UT and KO UT, 9 WT AOM, and 14 KO 
AOM. p<0.05 *, p<0.005 **  
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Figure 19: Similar macrophage markers between WT and KO mice. (A) Upon 
sacrifice of mice treated with AOM+DSS (AOM), the distal colon was harvested for 
RNA. After reverse transcription into cDNA, qRT-PCR was performed for macrophage 
markers. β-actin was used as an internal control, and data was analyzed using the dCT 
method. Error bars depict standard error. N=7 WT UT and KO UT, 9 WT AOM, and 14 
KO AOM. p<0.05 *, p<0.005 ** (B) After tumors were counted and measured, colons 
were distained in ethanol, and then incubated in 30% sucrose overnight. Whole colons 
were then frozen in OCT as Swiss Rolls, and 5µm sections were cut using a cryostat and 
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mounted onto charged slides. F4/80 (brown) IHC of untreated colons or AOM+DSS 
treated colonic tumors was then performed. Tissue was counterstained with hematoxylin 
(blue). UT, untreated.  
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Figure 20: KO mice exhibit diminished lamina propria CD4
+
 IFNγ+ cells. Upon 
sacrifice of AOM+DSS mice, lamina propria lymphocytes were isolated.  (A) CD4 and 
CD8 FACS staining of lamina propria cells from either untreated (UT) or AOM+DSS 
treated mice. (B) Lamina propria lymphocytes were stimulated ex vivo with anti-CD3 and 
anti-CD28 antibodies overnight, and then analyzed by FACS for CD4 and IFNγ 
expression. Plots are gated on CD4
+
 cells. Numbers in ‘A’ and ‘B’ denote percentages. 
(C) CD4
+
 cell percentages from ‘A’ are quantified. (D) The ratio of CD4+ to CD8+ cells 
from ‘A’ are quantified. (E) CD4+ IFNγ+ cell percentages from ‘B’ are quantified. Error 
bars depict standard deviation. N=3 WT UT and KO UT in ‘C’ and ‘D’, and 2 in ‘E’. 
N=9 WT AOM and KO AOM in ‘C-E’. p<0.05 *  
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Figure 21: Wnt activation and β-catenin mutations are decreased in KO mice. (A) 
RNA was isolated ex vivo from distal colon samples and reverse transcribed into cDNA. 
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qRT-PCR of Wnt pathway molecules from untreated (UT) or AOM+DSS treated distal 
colon samples was performed. β-actin was used as an internal control, and data was 
analyzed using the dCT method. Error bars depict standard error. N=7 WT UT and KO 
UT, 9 WT AOM, and 14 KO AOM. (B) Exon three of β-catenin was sequenced after 
PCR amplification from distal colon cDNA samples. Graph depicts percent of mice with 
mutations. N=3 WT UT and KO UT, 9 WT AOM, and 14 KO AOM. (C) Number of β-
catenin mutations in individual WT mice treated with AOM+DSS. (D) β-catenin exon 3 
sequence. Underlined codons are sites of GSK3β phosphorylation. Capitalized and red 
residues signify mutated bases. (E) β-catenin (brown) IHC of a normal section of colon, 
and of a colonic tumor from Swiss Rolls of AOM+DSS treated mice. Slides were 
counterstained with hematoxylin (blue). p<0.05 *, p<0.005 ** 
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Figure 22: WT and KO mice demonstrate similar DNA repair machinery.  cDNA 
from distal colon samples was reverse transcribed from RNA. (A) qRT-PCR was 
performed for various DNA repair molecules from either untreated (UT) or DSS treated 
samples at day 8. N=5. (B) The same as ‘A’, but from UT or AOM+DSS treated samples. 
N=7 WT UT and KO UT, 9 WT AOM, and 14 KO AOM. β-actin was used as an internal 
control, and data was analyzed using the dCT method. Error bars depict standard error. 
p<0.05 *, p<0.005 **  
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Figure 23: BMT verifies a hematopoietic intrinsic role. C57BL/6 mice were lethally 
irradiated with two doses of 550cGy, and then reconstituted 24hrs later with either 2x10
6
 
WT or KO BM cells injected iv into the lateral tail vein. After 12 weeks, mice were either 
left untreated (UT) or were treated with the AOM+DSS regimen, and then sacrificed 16 
weeks later. (A) FACS staining of PEC cells from BMT mice. Top: F4/80 vs SSC. 
Numbers denote percentages. Bottom: gp96 intracellular stain of gated F4/80
+
 cells from 
above. Isotype antibody was used as a control. (B) Percent weight change over time of 
UT or AOM+DSS treated BMT mice. N=4 WT UT, 6 KO UT, 15 WT AOM, and 16 KO 
AOM. (C) Quantification of tumor burden as the number of tumors times the average 
tumor size. Error bars depict standard deviation. N=12 WT and 11 KO. p<0.05 * (D) 
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F4/80 (brown) IHC of colonic tumors from Swiss Rolls of BMT mice treated with 
AOM+DSS. WT, WT→WT. KO, KO→WT.  
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Figure 24: Model of the promoting roles of macrophage-specific gp96. (A) Under 
basal conditions, gut epithelial cells create a physical barrier so that commensal bacteria 
cannot penetrate. Within the lamina propria, macrophages secrete IL-10, maintaining a 
tolerant environment. (B) DSS breaks apart tight junctions holding together epithelial 
cells, creating gaps between the cells and deteriorating the physical barrier. Commensal 
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bacteria are now able to cross into the lamina propria, where gp96
+
 macrophages 
recognize bacterial constituents via cell surface TLRs. This activation leads to production 
of proinflammatory cytokines, causing inflammation and colitis. (C) In the AOM+DSS 
model, DSS causes colitis in the same manner as described in ‘B’. Besides cytokines, 
proinflammatory macrophages are known to secrete reactive oxygen and nitrogen species 
(RONS) which can directly insult DNA. The carcinogen AOM is also able to cause DNA 
mutations. In particular, β-catenin is frequently mutated (stars) in this model. As well, the 
inflammatory environment leads to increased Wnt signaling in enterocytes. This leads to 
increased proliferation of epithelial cells, and in conjunction with mutations in 
oncogenes, leads to the formation of adenomas.  
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Chapter 5 
 
Concluding Remarks 
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Conclusions:  
Our study of the biology of gp96 has led to the discovery of the Drosophila ortholog 
gp93, identifying a simpler system by which to further examine gp96 structure and 
function. The following are our conclusions:  
1. Drosophila Gp93 is the ortholog of mammalian gp96.  
a. Gp93 rescues gp96 client expression.  
b. Gp93 physically interacts with TLR9.  
c. Gp93 and gp96 can dimerize.  
2. Gp96/Gp93 undergoes N-terminal dimerization.  
a. A137 of gp93/C138 of gp96 is important for N-terminal dimerization.  
b. N-terminal dimerization does not affect chaperone function of gp93.  
3. Gp96/Gp93 contains an N-terminal CBD.  
a. Residues 658-75 in gp93 are important for chaperone function.  
b. Tyrosines 674 and 675 are important for gp93 function. 
4. CNPYa and CNPYb rescue β2 expression.  
5. Drosophila CNPYb is the ortholog of mammalian CNPY3.   
a. CNPYb and CNPY3 bind both gp93 and gp96.  
b. CNPYb is a TLR-specific cochaperone for gp93.  
6. Disulphide bond formation is important for CNPYb function.  
a. Cysteines 36, 39, 92, and 183 of CNPYb are important for TLR4 
expression.  
b. Cysteines 39 and 183 of CNPYb are important for TLR2 expression.  
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The study of macrophage-specific gp96 has demonstrated a promoting role in 
both colitis and colitis-associated colon cancer. This work thus identifies gp96 in 
macrophages as a potential therapeutic target. The following are our conclusions:  
1. KO mice are less susceptible to DSS-induced colitis, exhibiting decreased:  
a. Pathology score  
b. Colonic shortening 
c. Stool consistency 
d. Inflammatory cytokine expression 
2. KO mice are less susceptible to AOM+DSS colitis-associated colon 
cancer, demonstrating decreased:  
a. Pathology score 
b. Tumor burden (size and number)  
c. IL-17, IL-23, and TNFα expression 
d. CD4+ IFNγ+ Th1 cells 
e. Wnt signaling  
3. Macrophage-specific gp96 does not affect:  
a. Macrophage polarization   
b. Macrophage infiltration 
c. DNA repair pathways  
4. Macrophage-specific gp96 promotes β-catenin mutation after AOM+DSS 
treatment.  
5. Decreased tumor burden in KO mice is a hematopoietic effect.  
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Outstanding Questions:  
Drosophila gp93  
1. What are the endogenous clients of gp93 in Drosophila?  
 As previously mentioned, the following molecules are present in Drosophila: 
Toll, Toll-related proteins, αPS1, αPS2, αPS3, αPS4, αPS5, βPS, and βν. Since gp96 chaperones 
TLRs and various integrins, it is quite possible that all or some of these molecules may be 
endogenous clients of gp93. To explore this question, either S2 cells or flies can be used. 
S2 cells are a Drosophila hemocyte (similar to a macrophage) cell line (158). RNAi 
techniques can be used to knockdown gp93 expression, and then the expression of the 
potential client proteins can be analyzed. Immunoprecipitation experiments can be 
performed to determine whether gp93 and the various ‘clients’ can physically interact. As 
well, if loss of gp93 results in loss of Toll, then knockdown cells will be resistant to Toll 
ligation. Cells can either be transfected with a constitutively activated form of SPZ 
(C106, the Toll ligand), or they can be treated with recombinant C106. Then the 
activation of downstream targets can be analyzed, such as Drosomycin. If gp93 
knockdown results in loss of expression of any of these molecules (by FACS or WB), and 
if gp93 physically interacts with them, then we can conclude that these molecules are 
clients of gp96.  
 A gp93 knockdown fly can also be used. Such a fly was already characterized, but 
they do not survive past the third instar larval stage (157). However, other strains of flies 
with mutations within the gp93 gene exist which are available from the Bloomington 
Drosophila Stock Center and are awaiting characterization. Whole fly lysates can be 
prepared from WT and KO flies for WB and IP to determine expression of the potential 
 133 
 
client proteins, and whether or not they physically interact with gp93. Furthermore, flies 
can be easily infected with fungus and then probed for Toll downstream target genes to 
determine if Toll remains intact in KO flies. Therefore, either S2 cells or flies can be used 
to determine the endogenous clients of gp93.  
 
2. Is CNPYb the endogenous cochaperone for gp93?  
Although CNPYb appears to act as a cochaperone for gp93 in relation to TLR2 
and TLR4, we would like to investigate whether or not CNPYb is also an endogenous 
cochaperone for gp93. However, this question relies on the answer to the former 
question. If Toll or the Toll-related proteins prove to be endogenous clients for gp93, then 
it would be interesting to find out if CNPYb aids gp93 in their folding. S2 cells can be 
used for immunoprecipitation experiments to determine not only if gp93 binds CNPYb, 
but if tri-molecular complexes can be found among chaperone, cochaperone, and client. 
RNAi can also be used to knockdown CNPYb expression in WT S2 cells, to determine if 
client expression is decreased. Toll signaling can also be analyzed in these cells to 
determine if it’s affected.  Such experiments will definitively prove whether or not 
CNPYb is an endogenous gp93 cochaperone.  
 
3. What is the endogenous role of CNPYa in gp93 biology?  
Once again, this question relies upon the elucidation of the endogenous clients of 
gp93. Similar experiments as the ones proposed in ‘question 2’ can be used to determine 
whether or not CNPYa is a cochaperone for gp93. Immunoprecipitation experiments with 
S2 lysate can determine whether or not CNPYa physically interacts with gp93 or any of 
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its clients. RNAi specific for CNPYa will demonstrate if the expression of any of these 
client proteins is affected. Since our results demonstrate increased β2 expression in cells 
containing CNPYa, it is possible that CNPYa may chaperone the Drosophila beta 
integrins. Collectively, these results will demonstrate whether or not CNPYa is a 
cochaperone of gp93, either positively or negatively regulating various clients.  
 
4. What else can we learn from gp93 and CNPYb mutations?  
Mutational analysis of both gp93 and CNPYb has already gained insight into the 
model of action of both of these molecules. Again, the purpose of characterizing the 
Drosophila system was to gain knowledge which could be applied to the mammalian 
gp96 system. In this respect, we have already proven successful demonstrating the role of 
a C-terminal cysteine in dimerization and characterizing the CBD (19, 155). We wish to 
further this study to learn more. For instance, gp93
2YA
 demonstrates the importance of 
these two tyrosine residues in gp93 function. The corresponding mutation in gp96 might 
uncover a similar defect. This data implies the role of tyrosine phosphorylation in 
chaperone function. Therefore, identification of the tyrosine kinase involved may prove 
beneficial in designing therapeutic targets which regulate gp96 activity.  
CNPY3 M145K has defects in TLR interaction, trafficking, and signaling, with 
differences among varying TLRs (49). The reason for these differences is unknown. The 
corresponding residue in CNPYb is L133. Both methionine and leucine are hydrophobic 
residues, while lysine is basic. Therefore, L133 in CNPYb may play a similar role to 
M145 in CNPY3. Since the Toll-like family in Drosophila is smaller than the mammalian 
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TLR family, the mutant CNPYb L133K may therefore prove to be a useful tool in 
understanding the differential regulation of various TLRs/Toll by this residue.  
 
5. Does gp93 play a role in the UPR of Drosophila?  
As a major chaperone inside the ER, gp96 plays a role in the UPR. While general 
protein translation is stopped, ER chaperones take part in chaperoning unfolded proteins 
to thereby restore homeostasis. The UPR response is conserved from mammals down to 
Drosophila, with key molecules such as BiP/grp78 and XBP1 being highly conserved. 
Since gp93 is the ortholog of gp96, it is therefore possible that gp93 also plays a role in 
the Drosophila UPR. S2 cells treated with gp93-specific RNAi can be treated with 
tunacamycin to induce a UPR response. If gp93 knock down cells are more sensitive to 
UPR induction, this will imply that gp93 is required for a proper UPR response; if a UPR 
response cannot restore homeostasis, then the cell will undergo apoptosis. Furthermore, 
WT S2 cells can also be treated with tunacamycin and probed for gp93 levels. Although 
general protein translation is halted, the translation of UPR specific genes is increased, 
such as the ER chaperones. Therefore, if gp93 expression is increased after tunacamycin 
treatment, then this will imply that gp93 plays a role in the Drosophila UPR.  
 
Macrophage specific gp96  
1. Are reactive oxygen & nitrogen species (RONS) reduced in KO mice?  
The mutation rate of β-catenin was drastically different between WT and KO 
mice, yet no differences in DNA repair were seen. Since both mice were treated with 
AOM, we wondered if β-catenin mutations in particular were the result of another toxic 
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agent. It is known that proinflammatory macrophages produce RONS which can directly 
cause mutations. Since KO macrophages lack TLRs and are thus not as highly activated 
as WT macrophages, we hypothesized that there must be drastically reduced levels of 
RONS in KO mice. If so, this could explain the differences seen in β-catenin mutation.  
 
2. Does the role of macrophage-specific gp96 differ in other cancer types?  
Our data demonstrate that macrophage-specific gp96 promotes colitis associated 
colon cancer. We have not yet tested other models of cancer with our mice. However, the 
literature demonstrates that some molecules may play promoting roles in one cancer type, 
and protective roles in another. One case in point is MyD88. Although MyD88 is 
protective in the AOM+DSS model, it has proven promoting in many other models (97). 
In a very similar model of colitis-associated colon cancer using AOM+Oxa, MyD88 
actually played a promoting role (105). Yet in the absence of IL-10 in a model that uses 
six injections of AOM without DSS, MyD88 promotes cancer (159). MyD88 is also 
tumor-promoting in the MCA-induced fibrosarcoma model, the DMBA+TPA skin 
papilloma model, and in the spontaneous intestinal tumor model of APC
Min
 mice (95, 96). 
Therefore, the role of macrophage-specific gp96 must be elucidated in other cancer 
models to determine its effects. It will be interesting to compare tumors in different 
tissues, as well as spontaneous versus inflammation-induced models. A better 
understanding will determine the applicability of therapeutics targeting gp96 in 
macrophages for different cancer types.  
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3. What is the role of integrins?  
Gp96 chaperones select integrins (6). It is possible that the loss of some integrins 
can be compensated by others. In the AOM+DSS model, gp96 KO macrophages can still 
migrate to the lamina propria and to the tumor microenvironment, demonstrating little 
overall effect by loss of integrins. The gp96-dependent integrin αv, however, leads to 
spontaneous colitis when knocked out of myeloid cells, including macrophages, 
monocytes, neutrophils, and some DCs (6, 160). In particular, αvβ1 on intestinal 
macrophages is important for production of IL-10, and thus the maintenance of an 
immunosuppressive environment (161). Since our KO mice do not develop spontaneous 
colitis, it is likely that this phenotype was caused by a different myeloid cell population. 
However, this demonstrates that a single integrin subunit on a restricted cellular 
population can drastically impact colitis. Therefore, it will prove interesting to determine 
if any of the integrin subunits knocked down in our KO macrophages plays a role in the 
protective phenotype seen with our mice. On way to deduce the role of integrins is to 
create a transgenic knock-in mouse harboring the gp96
E103A
 mutation, and then treating it 
with AOM+DSS. This mutant gp96 is able to chaperone integrins, but appears devoid of 
TLR chaperone function (3). Therefore, if the phenotype is recapitulated, then integrins 
must not play a role in our model.  
 
4. Are there differences in the gut microbiota?  
The gut microbiota plays an immense role in the induction of DSS-colitis and 
colon cancer, and inflammation alone can alter the composition of the gut microbiota 
(162). Within the intestine, IL-10 expression is required for Treg development which 
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dampens T cell driven inflammation caused by commensals, thereby maintaining 
homeostasis (163, 164). Therefore, IL-10 KO mice get spontaneous colitis. However, IL-
10 KO mice do not develop colitis when housed in germ free conditions, and mono-
association with the B. vulgatus bacterium causes an intermediate phenotype. 
Furthermore, although IL-10 KO mice treated with AOM develop colon cancer, polyp 
formation is absent when housed in germ free conditions, and mono-association again 
produced an intermediate phenotype. Therefore, the development of both colitis and 
colon cancer is dependent on the presence of commensals (159).  
Another group demonstrated that mono-colonization of IL-10 KO mice with E. 
coli NC101 together with AOM led to invasive carcinomas. However, deletion of the 
polyketide synthase (pks) genotoxic island from E. coli NC101 resulted in decreased 
tumorigenesis. The presence of Pks+ E. coli is even associated with a large percent of 
IBD and colon cancer patients (162). Furthermore, different commensal species can 
produce varying effects. For instance, segmented filamentous bacteria (Clostridium) are a 
potent inducer of T cell maturation within the gut (165). Therefore, we are interested in 
analyzing the microbiota composition in WT and KO mice, both untreated and under 
DSS and AOM+DSS treatments. It is possible that the composition of the microbiota in 
KO mice is altered, being associated with less disease.  
 
5. Does gp96 promote EMT conversion and the appearance of stemness genes?  
 Epithelial to Mesenchymal transition (EMT) is a normal process occurring in 
embryogenesis, organogenesis, and tissue regeneration. However, it abnormally occurs in 
cancer, where the dedifferentiation of epithelial cells promotes tumor progression and 
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metastasis (166). This phenomenon is associated with the loss of epithelial markers, such 
as E-cadherin, cytokeratins, and CD326, with a concomitant increase in mesenchymal 
markers such as vimentin and CD90. This transition has also been associated with the 
appearance of stemness genes, such as CD133, Sox2, Nanog, and Oct4 (167). 
Furthermore, the notion of a cancer stem cell postulates that within a tumor, a few cells 
are able to self-renew and thus contribute to tumor growth. Being stem cell-like, these 
cells will also express various stemness genes (168). Therefore, we would like to 
determine whether macrophage-specific gp96 can promote EMT conversion and the 
appearance of stemness genes as a means to promote tumorigenesis.  
 WT and KO macrophages can be stimulated ex vivo with TLR ligands and AOM 
to simulate our in vivo model. Either the cells directly, or culture supernatant can then be 
used to activate an enterocyte cell line, such as YAMC (169). As well, these cells can be 
treated directly with IL-17, IL-23, or TNFα, the three cytokines which were significantly 
reduced in KO mice. The YAMC cells will then be analyzed for Wnt pathway activation, 
β-catenin mutation, EMT transition, and stemness genes. This data may further prove 
mechanistically how macrophage-derived gp96 promotes tumorigenesis.  
 
6. What is the role of gp96 in microglia and seizures? 
Kinetic scrutiny of our KO mice demonstrated the most prominent phenotype of 
these mice: age-related spontaneous seizures characterized by abnormal behavior and 
hyperactivation of multiple muscles at once. Although detailed observations have not 
been made, the onset is around 6 months of age and incidence is roughly 90-95%. 
Furthermore, the severity of episodes also seems to increase with age, lasting roughly 30-
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90 seconds. The incidence in WT littermate controls was 0%. A neurological disorder, 
better characterization of brain macrophages, microglia, is warranted. Furthermore, the 
trigger for such episodes needs to be determined. However, anxiety, fear, increased heart 
rate, and /or adrenalin may be possible causes, as episodes frequently occur upon 
transferring the cage into the hood and opening the lid, an action which may startle the 
mice. Therefore, the study of macrophage-specific gp96 may gain valuable insight into 
seizure biology.  
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